Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trial s.gov 
Identifier: 
Indication: 
Protocol ID: 
[COMPANY_009] Sciences Medical 
Monitor 
Protocol Version/Date: (rJ GILEAU 
CLINICAL STUDY PROTO COL 
A Phase 2, Rando mized, Double -Blin d, Placebo-Controlled Study 
Evaluating the Safety, Tole rabili ty, and Efficacy of GS-[ADDRESS_1008887] 
Foste r City, CA [ZIP_CODE] 
124915 
Not Applicable 
Not Available 
Nona lcoholic steato hepatitis (NAS H) 
GS-US-426-3989 
Nam e: 
Telephone: 
Fax: 
Ema il: 
Original: 
Ame ndm ent 1: IPI[INVESTIGATOR_738381] 
[ADDRESS_1008888] OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 12
1. INTRODUCTION .............................................................................................................................................. 16
1.1. Background ............................................................................................................................................ 16
1.2. GS-0976 ................................................................................................................................................. 17
1.2.1. General Information ............................................................................................................. 17
1.2.2. Nonclinical Pharmacology ................................................................................................... 17
1.2.3. Nonclinical Toxicology ........................................................................................................ 17
1.2.4. Nonclinical Pharmacokinetics .............................................................................................. 18
1.2.5. Clinical Trials of GS -0976 ................................................................................................... 19
1.3. Rationale for the Current Study ............................................................................................................. 24
1.3.1. Rationale for this Study ........................................................................................................ 25
1.4. Risk/Benefit Assessment for the Study .................................................................................................. [ADDRESS_1008889] Selection ............................................................................................ 31
4.2. Inclusion Criteria .................................................................................................................................... 31
4.3. Exclusion Criteria ................................................................................................................................... 32
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 35
5.1. Randomization, Blinding and Treatment Codes .................................................................................... 35
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 35
5.2. Description and Handling of Study Drugs ............................................................................................. 36
5.2.1. Form ulation .......................................................................................................................... 36
5.2.2. Packaging and Labeling ....................................................................................................... 36
5.2.3. Storage and Handling ........................................................................................................... 36
5.3. Dosage and Adminis tration of GS -0976/PTM GS -0976 ...............................................................
......... 36
5.4. Prior and Concomitant Medications ....................................................................................................... 37
5.5. Accountability for GS -0976/PTM GS -[ADDRESS_1008890] Enrollment and Treatment Assignment ..................................................................................... 39
6.2. Pretreatment Assessments ...................................................................................................................... 39
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 3 15 December [ZIP_CODE].2.1. Screening Visit ..................................................................................................................... 39
6.3. Baseline/Day 1 Randomization and Assessments .................................................................................. 41
6.4. Treatment Assessments .......................................................................................................................... 43
6.4.1. Week 1 Visit (±3 days) ......................................................................................................... 43
6.4.2. Week 4 Visit (±3 days) ......................................................................................................... 44
6.4.3. Week 8 Visit (±3 days) ......................................................................................................... 44
6.4.4. Week 12 Visit (±7 days) ....................................................................................................... 45
6.4.5 . Unscheduled Visit ................................................................................................................ 46
6.4.6. Follow -Up Visit (±5 days) ................................................................................................... 47
6.5. Assessments for Premature Discontinuation from Study ....................................................................... 48
6.6. Criteria for Discontinuation of Study Treatment .................................................................................... 48
6.7. .48
6.8. Description of Assessments ................................................................................................................... 49
6.8.1. Clinical Laboratory Analytes ............................................................................................... 49
6.8.2. Physical Examination ........................................................................................................... 50
6.8.3. Vital Signs ............................................................................................................................ 50
6.8.4. Medical History ................................................................
.................................................... 51
6.8.5. Pharm acogenomic Testing ................................................................................................... 51
6.8.6. Health Related Quality of Life (HRQoL) ............................................................................. 51
6.8.7. Electrocardiogram ................................................................................................................ 51
6.8.8. FibroScan®........................................................................................................................... [ADDRESS_1008891] (IRB)/Independent Ethics Committee (EC) 
Revie w and Approval ........................................................................................................... 68
9.1.3. Informed Consent ................................................................................................................. 68
9.1.4. Confidentiality ................................................................
...................................................... 69
9.1.5. Study Files and Retention of Records .................................................................................. 69
9.1.6. Case Report Forms ............................................................................................................... 70
9.1.7. Study Drug Accountability and Return ................................................................................ 71
9.1.8. Inspections ............................................................................................................................ 71
9.1.9. Protocol Compliance ............................................................................................................ 71
9.2. Sponsor Responsibilities ........................................................................................................................ 72
9.2.1. Protocol Modifications ......................................................................................................... 72
9.2.2. Study Report ......................................................................................................................... 72
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 72
9.3.1. Payment Reporting ............................................................................................................... 72
9.3.2. Access to Information for Monitoring .................................................................................. 72
9.3.3. Monitoring and Oversight of Biomarker Specimens ............................................................ 72
9.3.4. Access to Information for Auditing or Inspections .............................................................. 73
9.3.5. Study Discontinuation .......................................................................................................... 73
10. REFERENCES ................................................................................................................................................... 74
11. APPENDICES .................................................................................................................................................... 77
Appendix 1. Investigator Signature [CONTACT_3490] .................................................................................................... 78
Appendix 2. Study Procedures Table for GS -US-426-3989 ....................................................................... 79
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Po
tential, and 
Contraceptive Requirements ................................................................................................... 81
Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.[ADDRESS_1008892]
Foster City, CA [ZIP_CODE]
Study Title : A Phase 2, Randomized, Double- Blind, Placebo- Controlled Study  
Evaluating the Safet y, Tolerability, and Efficacy of GS -0976 in Subjects 
with Nonalcoholic Steatohepatitis
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:124915
Not Applicable
Not Available
Study Centers 
Planned:Approximately  50 centers in the [LOCATION_002]
Objectives: The primary  objective of this study  is to evaluate the safet y and 
tolerability  of GS -0976 in subjects with nonalcoholic steatohepatitis 
(NASH) as assessed b y magnetic resonance imaging
-proton density  fat 
fraction (MRI -PDFF ) and magnetic resonance elastrograph y (MRE) or a 
historical liver biopsy  consistent with NASH and non -cirrhotic fibrosis.
The exploratory  objectives of this study  are listed in Section 2.
Study Design: This is a Phase [ADDRESS_1008893] up to approximately  22weeks, which 
includes a 6-week Screening period, a 12 -week treatment period during 
which study  drugs will be administered, and a 4 -week follow -up period.
The screening period may be extended under special circumstances with 
the explicit approval of the Medical Monitor.
Subjects meeting the study ’s entry  criteria will be randomly  assigned in a 
2:2:1 ratio to 1 of 3 treatment groups as shown in the figure below:
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 7 15 December 2016Study  drugs will be administered for a total of 12 weeks. Randomization 
will be stratified by  [CONTACT_738399] b y medical history, use of medication for indication of 
diabetes mellitus, or based on Screening lab values if previously  
undiagnosed (i.e., hemoglobin A1c ≥ 6.5% OR fasting plasma 
glucose ≥ 126 mg/dL).
Number of 
Subjects 
Planned: Approximately  125 subjects
Target 
Population:Males and non- pregnant, non -lactating females between 18-75 yearsof 
age without cirrhosis and with NASH as assessed by [CONTACT_9268] -PDFF and 
MRE or a historical liver biopsy  consistent with NASH and non -cirrhotic 
fibrosis .
Duration of 
Treatment : Subjects will be treated for 12 weeks.
Diagnosis and 
Main Eligibility  
Criteria:Key inclusion and exclusion criteria are as follows :
Key Inclusion Criteria:
Meets the following conditions:
a)A clinical diagnosis of nonalcoholic fatt y liver disease (NAFLD) with 
imaging or a liver biopsy documenting fatty  liver within two y ears 
prior to Screening (if necessary ,an ultrasound may  be performed 
during Screening to confirm NAFLD ), and 
b)Screening MRI -PDFF with ≥ 8% steatosis , and
c)Screening MRE with liver stiffness ≥ 2.
5kPa.  
Note: criterion a. must be met before evaluating criteria b. and c.
OR
tlQ 
C: · c 
a, 
u 
Vl 
6 Weeks Group A (n=S0) 
GS-0976 5 mg+ 5 mg-PTM + 2 x 10 mg-PTM 
orally once daily 
Group B (n=S0) 
2 x GS-097610 mg+ 2 x 5 mg-PTM 
orally once daily 
Group C (n=25) 
2 x 5 mg-PTM + 2 x 10 mg-PTM 
orally once daily 
12 Weeks > "'C 
:::, 
ai 
0 
"'C 
C: 
I.LI 
--.... 
C. 
:::> 
15 u.. 
4 
Weeks 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 8 15 December 2016A historical l iver biopsy  within 12 months of Screening consistent 
with NASH (defined as the presence of steatosis, lobular 
inflammation, and hepatocellular ballooning )with fibrosis, but not 
cirrhosis, and
No documented weight loss > 5% between the date of the liver biops y 
and Screening.
Platelet count ≥ 100,000/mm3
Creatinine Clearance (CL cr) as calculated by  [CONTACT_16424] -Gault 
equation ≥ 60 ml/min
Key Exclusion Criteria:
Pregnant or lactating females;
ALT > [ADDRESS_1008894];
Other causes of liver disease including autoimmune, viral, and 
alcoholic liver disease;
Cirrhosis of the liver as defined b y any of the following:
a)Cirrhosis on historical liver biopsy  (e.g. NASH CRN classification
stage 4 or equivalent);
b)Evidence of cirrhosis on liver imaging (e.g. ultrasound, CT, or MRI ) 
including a nodular liver surface, splenomegal y, or portal venous 
collaterals;
c)Prior history of decompensated liver disease, including ascites, 
hepatic encephalopath y or variceal bleeding;
d)Screening FibroSURE/FibroTest®≥ 0.75, unless a historical liver 
biopsy  within 12 months of Screening does not reveal cirrhosis. In 
patients with Gilbert’s syndrome or hemol ysis, 
FibroSURE/FibroTest®will be cal culated using direct bilirubin 
instead of total bilirubin . 
BMI < 18 kg/m2;
INR > 1.2 ,unless on anticoagulant therapy ;
Total bilirubin > [ADDRESS_1008895], except with diagnosis of Gilbert’s 
syndrome;
Refer to Sections 4.2and 4.3for complete listing of inclusion and 
exclusion criteria.
Subjects with laboratory  abnormalities outside of the above parameters 
may be approved for inclusion in the trial with app roval from the Medical 
Monitor.
GS-0976 
Protoco l GS-US-426 -3989 
[COMPANY_009] Sciences , Inc. 
Study 
Procedures / 
Freque ncy: 
CONFIDENTIAL Final 
Amendment 1 
After signing the info1med consent fo1m , subjects will complete a 
Scree ning visit which will inclu de the following assess ments: complete 
medical histo1 y , ph ysical exam ination (P E), vital signs , laborato 1 y 
assessme nts (bloo d chemistiy , hematology , coag ulatio n panel , 
hemoglobin Ale, and HIV-1, HBV, and HCV serology) , sernm 
pregnancy test (for females of child-bearing potential), urine drng test, 
standard 12-lead ECG , ulti·asoun d (if necessa 1y), review of adverse 
events, concomita nt m edicatio ns, and M RI-PDFF and M RE 
examinatio ns. 
After the Scree ning period and a randomizat ion visit at Baseline/Day 1, 
study visits will occur on Weeks 1, 4, 8, 12, and a Follow-U p visit [ADDRESS_1008896] dose of study diugs. At minimum, vital signs, 
sympto m di·iven PE, safety laborato1y tests (blood chemistiy , 
hematology, coag ulation panel, and lipid profile), review of adverse 
events and concomita nt medicat ions will be done at eve1 y visi t. 
Eligible su bjects will be randomized to one of 3 ti·eatme nt groups . Prior 
to initial dosing , required Baseline/Day 1 assess ments will be perfo1med 
and will include symptom di·iven PE, vital signs (including waist 
circumference), laborato1y assessments , pregnancy tests (for females of 
child-bea ring potential), urine, blood, and stool collectio n for biomarker 
assessme nt, Qua lity of Life (QoL) questionnai res, standard 12-lead ECG, 
FibroScan® (if available), review of adverse events and concomitant 
medicatio ns. 
While on study, subjects will undergo the following procedures and 
laborato 1 y assessme nts: 
• M RE and M RI-PDFF at Week 12 
• FibroScan® at Base line/Day 1 and Week 12 (if available) 
• S ingle PK samp ling at Weeks 1, 4, 8, and 12 
• Bloo d collect ion for Bioma rkers at Baseline/Day 1, and at Weeks 1, 
4, and 12 
• U rine collect ion for Bioma rkers at Baseline /Day 1, and at Weeks 1, 4, 
and 12 
• 1 2-lead ECGs at Baseline/Day 1 and Week 12 
• Hematology , blood chemistiy, fasting lipid profile , PT, PTT, and INR 
at Baseline/Day 1, and at Weeks 1, 4, 8, 12, and Follow-Up visit 
• Hemog lobin Ale (HbAle) at Base line/Day 1 and Week 12 
• Stool collect ion for Biomarkers at Baseline/Day [ADDRESS_1008897] , Dose, 
and Mode of 
Admini stration: 
Reference Therap y, 
Dose, and Mode of 
Admini stration: 
Criteria for 
Evaluation: 
Safety: 
CONFIDENTIAL Final 
Amendment 1 
• U rine pregnancy test (females of childbearing potential only) at 
Baseline/Day 1, and at Wee ks 4, 8, 12, and Fo llow-Up visit 
• SF-36, WPAI , and CLDQ at Baseline/Day [ADDRESS_1008898] will be perfonned for 
females of child bearing potential only. 
• Treatme nt Group A: GS-0976 5 mg (1 x 5 mg capsule, 1 x 5 m g-PTM 
capsule, 2 x 10 mg -PTM capsules) admini stered orally once dai ly; 
n=50 subjects 
• Treatme nt Group B: GS-0976 20 mg (2 x 10 mg capsule, 
2 x 5 mg -PTM capsules) admini stered orally once daily; 
n=50 subjects 
• Treatme nt Group C: GS-0976 Placebo (2 x 5 mg -PTM capsules , 
2 x 10 mg-PTM capsules) achnin istered orally once dai ly; 
n=25 subjects 
Placebo-to -match 5 mg (5 mg-PTM) GS-0976 capsules and 
placebo -to-match 10 mg capsules (10 mg -PTM) are identical in size, 
shape, color and appearance to their conespond ing streng ths of active 
GS-0976 capsules. 
The prim aiy endpo int is the safety of GS-0976 in subjects with NAS H. 
Safety will be assesse d during the study throug h the repo1 ting of AEs , 
and by [CONTACT_738400]1y tests and vital sign assess ments at various time 
points during the study. Concoini tant medication usage will also be 
assessed throughout t he study . 
An indepe ndent, external Data Monitoring Comini ttee (DMC) that 
consists of two hepatolog ists and a PhD statist ician wi ll convene on ce 
[ADDRESS_1008899] 3 siinilar Grade 3 serious, tr eatment related 
Common Tenn inology Criteria for Adverse Events (CTCAE) observed in 
the trial. In the event of two siinilar Grade 4-CTCAE treatme nt related 
Page 10 15 December 2016 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 11 15 December 2016events or one Grade 5 -CTCAE treatment related event, the DMC will 
review the data and advise the sponsor regarding stoppi[INVESTIGATOR_738382].
Efficacy : Efficacy  will be assessed through a number of exploratory  endpoints. 
These exploratory  endpoints are described in Section 8.1.3.
Pharmacokinetic s: A single PK blood sample will be collected at each on-treatment visit for 
all subjects. Plasma concentrations of GS -
0976, and other metabolites as 
appropriate, will be determined for PK anal yses as applicable.
Statistical 
Methods:
Safety  Anal ysis: All safet y data collected will be listed and summarized, as appropriate, b y 
treatment group.
Efficacy  
Analy sis:The biological activity  of GS -0976 will be evaluated using biomarker 
variables. Because efficacy  endpoints will be evaluated for exploratory  
purpose, formal statistical comparisons will n ot be made for these 
endpoints. Ninety -five percent confidence intervals (95% CI) will be 
provided if applicable.
Exploratory  
Analy sis:Point estimates and 95% CI  will be calculated for all continuous 
exploratory  parameters (e.g. MRI -PDFF, MRE, FibroScan®). For 
categorical variables, descriptive statistics will be calculated with count 
and percentage of subjects in each category  by [CONTACT_1570].
Sample Size: Due to the exploratory  nature of this study , no formal power calculations 
were used to determin e sample size. The number of subjects was chosen 
based on clinical experience with other similar proof of concept studies.
This study  will be conducted in accordance with the guidelines of Good Clinical Practices 
(GCPs) including archiving of essential documents.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 12 15 December 2016GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
ACC acetyl -CoA carboxylases
AE adverse event
ALP alkaline phosphatase 
ALT alanine aminotransferase
Apo B apolipoprotein B
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC 0-last area under the plasma concentration -time curve from time [ADDRESS_1008900] 
measurable concentration
AUC inf area under the plasma/serum/PBMC concentration versus time curve 
extrapo lated to infinite time, calculated as AUC 0-last+ (Clast/λ z)
AUC partial partial area under the plasma/serum concentration versus time curve
AUC tau area under the plasma/serum/PBMC concentration versus time curve over the 
dosing interval
AUROC area under the receiver operating characteristic curve
BAP Biomarker Analysis Plan
BID twice a day
BMI body mass index
BUN blood urea nitrogen
BW body weight
C4 7
-alpha -hydroxy -4-cholesten -3-one
CFR Code of Federal Regulations
CI confidence interval
CK-18 cytokeratin 18
CLDQ Chronic Liver Disease questionnaire
CL/F apparent oral clearance
CL cr creatinine clearance
CL renal Renal clearance 
Clast last observed quantifiable serum/plasma/PBMC concentration of the drug
Cmax maximum observed concentration of drug
Cmin minimum observed plasma/serum concentration of drug
CRO contract (or clinical) research organization
CSR clinical study report
CT computed tomography
Ctau observed drug concentration at the end of the dosing interval
CTCAE Common Term inology Criteria for Adverse Events
CYP cytochrome P450
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 13 15 December 2016CYP3A cytochrome P4503A
DILI drug induced liver injury
dL deciliter
DMC Data Monitoring Committee
DNL de novo lipogenesis
DSPH Drug Safety and Public Health
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form(s)
EDC electronic data capture
ELF™Test enhanced liver fibrosis test
ESA erythropoiesis -stimulating agent
eSAE electronic serious adverse event
eSSR electronic special situations report
ET early termination
EU European Union
FAS Full Analysis Set
FDA ([LOCATION_002]) Food and Drug Administration
FGF19 fibroblast growth factor 19
FSH follicle stimulating hormone
GCP Good Clinical Practice (Guidelines)
GCSF granulocyte colony stimulating factor
GGT gamma glutamyl transferase
Hb hemoglobin
HbA1c hemoglobin A1c
HBsAg hepatitis B surface ant igen
HBV hepatitis B virus
HCC hepatocellular carcinoma
hCG human chorionic gonadotropin
Hct hematocrit
HCV hepatitis C virus
HCV Ab hepatitis C antibody
HDPE high density polyethylene
HIV human immunodeficiency virus
HIV-1 human immunodeficiency virus type 1
HLGT high-level group term
HLT high-level term
HOMA -IR homeostatic assessment of insulin resistance
HRQoL health related quality of life
IB Investigator Brochure
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 14 15 December 2016ICF Informed Consent Form
ICH International Conference on Harmonisation
ID Identification
IEC independent ethics committee/ institutional ethics committee
IND Investigational New Drug (Application)
INR international norm alized ratio
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
kg kilogram
LDH lactate dehydrogenase
LLT lower-level term
MAD multiple ascending dose
MCV mean corpuscular volume
MedDRA Medical Dictionary for Regulatory Activities
mg milligram
miRNA micro ribonucleic acid
mmHg millimeters of mercury
MPR metabolite -to-parent
MRE magnetic resonance elastography
MRI magnetic resonance imaging
MRI -PDFF magnetic resonance imaging –proton density fat fraction
NAFLD nonalcoholic fatty liver disease
NASH nonalcoholic steatohepatitis
NMR nuclear magnetic resonance spectroscopy
NOEL no-observed --effect-level
NOAEL no observed adverse event level
N/C not calculated
OATP organic anion -transporting polypeptide
oz ounce
PE physical exam
PG pharmacogenomics(s)
P-gp P-glycoprotein
PK pharmacokinetic(s)
PT preferred term
PT prothrombin time
PTM placebo -to-match
PTT partial prothrombin time
QD once daily
QoL quality of life
GS-[ADDRESS_1008901] representing the time for both ventricular 
depolarization and repolarization to occur
RAUC Ratio of Day 10 AUC 0-tau/ Day 1AUC 0-t
RBC red blood cell count
RNA ribonucleic acid
ROS reactive oxygen species
SADR serious adverse drug reaction
SAE serious adverse event 
SAP Statistical Analysis Plan
SD standard deviation
SF
-36 Short Form (36) Health Survey
SOC System  Organ Class
SOP standard operating procedure
SSR special situations report
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TEAE treatment -emergent adverse event
Tmax the time (observed time point) of C max
T1/2 an estimate of the terminal elimination half -life of the drug in, calculated by 
[CONTACT_337342] 2 by [CONTACT_90262] (λ z)
TPO Thrombopoietin
ULN Upper limit of the normal range
US [LOCATION_002]
Vz/F apparent volume of distribution of the drug
WBC White blood cell count
WHO World Health Organization
WPAI Work Productivity and Activity Impairment
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 16 15 December [ZIP_CODE]. INTRODUCTION
1.1. Background
Chronic liver disease and the consequences of end- stage liver disease are increasing globall y 
despi[INVESTIGATOR_121994]. This is due to the emerging 
epi[INVESTIGATOR_121995] y, metabolic syndrome, and diabetes mellitus that are leading to an increased 
incidence of nonalcoholic fatt y liver disease (NAFLD). Nonalcoholic fatty liver disease is 
characterized b y the excess accumulation of lipid droplets within the liver, also known as hepatic 
steatosis. Prevalence rates of NAFLD range from 6% to 37% worldwide { Ong 2007 , Vernon 
2011}. Nonalcoholic steatohep atitis (NASH), an aggressive form of NAFLD characterized by  
[CONTACT_738401], with or without fibrosis, is present 
in approximately  25% of patients with NAFLD. Nonalcoholic steatohepatitis is associated with 
increa sed liver -related mortality  {Ong 2007, Williams 2011 }. In the [LOCATION_002] (US), it has 
been estimated that 3% to 6% of the population, {Vernon 2011
, Wanless 1990 }, or the 
equivalent of up to [ADDRESS_1008902] NASH. NASH represents a significant and growing 
unmet medical need for which there are no currently  approved therapi[INVESTIGATOR_014]. Furthermore, as NA SH 
is a manifestation of the metabolic sy ndrome, risk factors for cardiovascular disease 
(eg,atherosclerotic disease, cardiac arrhy thmogenicity ) frequentl y coexist in these patients 
{Dietrich 2014 , Faramawi 2008 , Voulgari 2010 }. A treatment that targets the underl ying 
metabolic disorder could potentially  ameliorate these cardiovascular risks and associated 
morbidity  and mortality .
Nonalcoholic steatohepatitis is primarily  thought to occur as the result of the metabolic 
syndrome, the impact of obe sity, insulin resistance, and dy slipi[INVESTIGATOR_121996]. Simple 
steatosis is not sufficient to cause liver injury ; it is the presence of inflammation and 
hepatocellular injury  on the background of steatosis that defines NASH and results in the 
progression 
to end- stage liver disease and its complications. The “2 -hit” hypothesis of NASH 
suggests that in the setting of steatosis and metabolic dy sfunction, increased oxidative stress and 
the generation of reactive oxy gen species (ROS) likely  mediate the inflamma tory changes in the 
liver (steatohepatitis) that may  lead to progressive fibrosis {Dowman 2010, Kannel 1982 , Koek 
2011, Sumida 2013 }. The major pathway s in NA SH disease progression include those involved 
inmetabolic dy sfunction in the hepatocy te, and activation of hepatic stellate cells and 
macrophages leading to progressive inflammation and liver fibrosis. Advanced fibrosis and 
cirrhosis are characterized by  [CONTACT_722397]. I n addition, evidence suggests that lipotoxic intermediates of fatt y acids likely contribute 
to the etiology  of NASH {Neuschwander -Tetri 2010 }.  
Over time, NASH may  result in progressive liver fibrosis, ultimately  leading to cirrhosis in 
10-20% of affected patients. Advanced fibrosis (bridging fibr osis or cirrhosis) is associated with 
increased morbidity  and mortality  {Ekstedt 2015 , Yeh 2014 }. Patients with cirrhosis may  
develop hepatocellular carcinoma (HCC) and other complications of end -stage liver disease, 
including jaundice, fluid retention (edema and ascites), portal hy pertension and variceal 
bleeding, impaired coag ulation and hepatic encephalopathy . Decompensated liver disease, as 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 17 15 December 2016defined b y the development of one of the above complications, has a high mortality  and the onl y 
known effective treatment is liver transplantation. With the increasing prevalence of obesit y and 
obesity -related diseases, NASH is expected to become the leading indication for liver
transplantation, and the leading etiology  of HCC among liver transplant recipi[INVESTIGATOR_121997] 
{Afzali 2012, Wong 2014}.
1.2. GS-
0976
GS-0976 is a small molecule allosteric inhibitor that acts at the protein- protein homodimer 
interface of acet yl coenzy me A ( acetyl-CoA )carboxy lases (ACC) ACC1 and ACC2 ,to prevent 
dimerization. ACC1 and ACC2 are important regulators of fatt y acid metabolism. ACC1 
catal yzes the first step of de novo lipogenesis (DNL) b y converting acet yl-CoA to malony l-CoA 
while ACC2 regulates the entry  of fatty  acids into the mitochondria where beta oxidation can 
occur. Therefore, inhibition of ACC1 and ACC2 will reduce DNL and increase fatt y acid beta 
oxidation. GS -0976 is being developed for the treatment o f NASH .
1.2.1. General Information
For further information on GS -0976, refer to the curr ent Investigator Brochure (IB) for GS -0976.
1.2.2. Nonclinical Pharmacology
GS-[ADDRESS_1008903] been conducted.
The results of these pharmacody namic (PD) studies indicate that GS- [ADDRESS_1008904] 
the DNL, hepatic steatosis, insulin resistance, and body  weight/body  fat elevations produced in 
nonclinical models of metabolic disease without affecting food consumption or markers of liver 
function. In total, these studi es confirm the potential for GS -[ADDRESS_1008905] species was based on the in vitro and in 
vivo assessment of metabolism. I n in vitro experime nts using human hepatocy tes, 
nohuman- specific metabolites were identified and all metabolites det ected were also present in 
rat and/or dog hepatocy tes.
There were no adverse findings in safety  pharmacology  studies (central nervous sy stem, 
respi[INVESTIGATOR_738383]) at exposures ~ 50 fold above the predicted stead y-state 
clinical exposure (Cmax~110 ng/mL) after administration of 20 mg GS-0976 once dail y (QD) 
fasted . The genotoxicity  potential of GS -0976 was considered low as the compound is negative 
in the in vitro Ames, chromosome aberration studies and the in vivo mouse micronucleus stud y.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 18 15 December 2016Single doses of GS -0976 up to 1000 mg/kg were tolerated in rats and dogs. I n the 28 -day studies, 
the 
no-observed-adverse- effects levels ( NOAELs )for the rat and dog were 60 and 
100mg/kg/day respectively , the highest doses tested in the studies, affordi ng exposure margins 
of at least 23 (rat) and 63 (dog) times above the predicted steady -state clinical exposure after 
administration of 20 mg GS- 0976 QD fasted (240 ng•h/mL). In the 13 -week rat study , no dose 
limiting toxicity  was observed and the NOAEL was 60 mg/kg/day , the highest dose tested , 
providing an exposure margin of 23- fold above predicted stead y-state clinical exposure. In the 
13-week dog stud y, bilateral posterior cortical cataracts and histological evidence of cataracts
were observed at 90 mg/k g/day , with progression in severity  after a 28 -day recovery  period. 
There was no evidence of cat
aracts at doses ≤ 30 mg/kg/day . In the 13 -week dog stud y,the 
presence of cataracts was found at exposures approximately  82times above the predicted 
steady -state 
clinical exposure. No evidence of cataracts was observed at doses ≤ 30 mg/kg/day . 
The NOAEL for the 13 -week dog stud y was 30 mg/kg/day, providing an exposure margin of 
approximately  15fold above the predicted stead y-state clinical exposure at 20 mg.
Inthe rat em bryo-fetal development dose -range finding stud y, maternal toxicity  and fetal 
abnormalities (external and soft tissue malformations, and developmental variations) were 
observed at doses ≥ 50 mg/kg/day  in a dose -dependent manner. The no-observed-e ffect level 
(NOEL )for the embry o-fetal rat study  was 25 mg/kg/day at an approximate exposure margin of
5.8times above the predicted stead y-state clinical exp osure. I n the rabbit study , 100 mg/kg/day  
was not tolerated and maternal toxicity  (decreased body weight gain and food consumption) was 
observed at doses ≥ 25 mg/kg/day . While decreases in fetal wei ghts were observed at doses 
≥10mg/kg/day , no external malformations and developmental variations were observed at all 
doses.  The NOEL for the embry o-fetal rabbit study  was less than 10 mg/kg/day . At this dose, 
the predicted stead y-state clinical exposure margin is approximately  53. The observed 
embry o
-fetal effects were not unexpected as the deletion of ACC1 in mice is embry onically  
lethal.
1.2.4. Nonclinical Pharmacokinetics
GS-0976 is highly  protein bound in plasma, and the volume of distribution of GS-0976 across 
nonclinical species is greater than total bod y water (0.7 L /kg), suggesting that GS -0976 is well 
distributed. A significant fraction of the absorbed p arent compound is extracted by  [CONTACT_738402] -0976 is available to the target site (ie, the liver).
The metabolism of GS -[ADDRESS_1008906] demonstrated that 
the primary  metabolite of GS -0976 is the glucuronide conjugate.
Neither GS -0976 nor the metabolite, NDI -011535, inhibits t he cy tochrome P450 (CYP) enzy mes 
involved in drug metabolism. GS- [ADDRESS_1008907] cannulated Sprague- Dawley  rats to profile concentrations over time 
in plasma, urine, and bile. Overall, the pharmacokinetic (PK) profile in plasma and bile indicate 
that GS -0976 is rapi[INVESTIGATOR_738384], and the primary  route of 
elimination is via the bile.
1.2.5. Clinical Trials of GS-0976 
[IP_ADDRESS]. Study  0976- 101: Single Ascending Dose (SAD) Study
The first -in-human single ascending dose (S AD) study  (Protocol Number 0976- 101) was a 
randomized, placebo- controlled, double -blind study  performed in normal, healthy  adult subjects 
at one study  center in the [LOCATION_002] with a starting dose of 30 mg. The dosing in this study  is 
completed with PK and tolerability  data obtained following dosing of 30, 80, 200, 500, 800, and 
1000 mg in the fasted state and 200 mg following a high fat meal (fed state) to cohorts of 
8subjects (6 active and 2 placebo control per group). Final data from the SAD study  indicated 
that single doses of GS -0976 were tolerated across the dose range of 30 to 1000 mg. There were 
no deaths, serious adverse events (SAEs), or subject discontinuations due to adverse events 
(AEs) in this study . There were no clinicall y important treatment related or dose related trends in 
the incidence or severity  of treatment emergent adverse events (TEAEs), clinical laboratory , vital 
sign, ECG, or ph ysical examination assessments in this study . Abdominal discomfort, vessel 
puncture site pain, dizziness , and pres yncope, reported by  2subjects each (6% ove rall for fasted 
GS-0976), were the most frequentl y reported events in this study . Of the 27 TEAEs reported in 
the study , all were of Grade 1 severit y. The principal investigator [INVESTIGATOR_738385] 2 TEAEs to be 
probably  related (1 epi[INVESTIGATOR_738386]), 4 possibly  
related (1 epi[INVESTIGATOR_738387] 30 mg GS- 0976 fasted group and 1 epi[INVESTIGATOR_738388], abdominal discomfort, and diarrhea in the 500 mg GS-0976 fasted group), and 
21unrelated to stud y treatment. 
Pharmacokinetic parameters of GS -0976 are presented in Table 1-1.Plasma GS -0976 maximum
plasma concentration (C max)and overall exposure (AUC inf)generall y increased 
in a dose 
proportional manner across the range of 30to 500 mg, under fasted conditions , with greater than 
dose-proportional increases above 500 mg . Similar results were observed for plasma 
NDI-
011535 ( glucuronide metabolite of GS -0976). The apparent total body clearance (CL/F)and 
apparent volume of distribution (Vz/F) of GS -0976 decreased wi th increasing GS
-0976 doses of 
800 mg and 1000 mg. Urinary  excretion of unchanged GS -0976 was negligible. GS -0976 C max
was approximately  68% lower under fed compared to fasted conditions; however, overall plasma 
GS-0976 exposure (based on AUC 0-tand AUC 0-inf) was onl y approximately 9% to 14% lower 
under fed compared to fasted conditions, which may  not be a clinicall y significant difference. 
The median Tmaxand mean T1/[ADDRESS_1008908] quantifiable concentration and a prolonged absorption/distribution 
phase observed under fed compared to fasted conditions. Similar results were observed for 
plasma NDI -011535. Mean plasma NDI -011535 exposure was < 10% of GS -0976 plasma 
exposure, based on metabolite -to-parent (MPR) Cmaxand MPR AUC inf.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 20 15 December 2016Table 1-1. Summary of Single Dose Pharmacokinetic Parameters of GS-0976 
Following Administration of 30 mg to 1000 mg GS -0976 Under
Fasting Conditions and 200 mg GS -0976 Under Fed Conditions
PK 
Param eter
Mean +SDGS-0976 Dose (m g)
30 m g
Fasted
(N=6)a80 m g
Fasted
(N=6)a200 m g
Fasted
(N=6)a200 m g
Fed
(N=6)a500 m g
Fasted
(N=6)b800 m g
Fasted
(N=6)b1000 m g
Fasted
(N=6)
Plasm a
AUC 0-t
(ng*h/mL)176 [PHONE_15336] [PHONE_15337] + 537 1160 + 613 2930 +
24406420 [PHONE_15338],400 +
8400
AUC 0-inf
(ng*h/mL)179 [PHONE_15339] [PHONE_15340] + 616 1260 + 683 2960 +
24606460 [PHONE_15341],500 +
8410
Cmax
(ng/mL)79.7 [PHONE_15342] [PHONE_15343] [PHONE_15344] [PHONE_15345] +
11502570 [PHONE_15346] [PHONE_15347]
Tmax(h)c1.26 
(0.23, 2.00)2.00 
(1.50, 2.00)1.50 
(1.01, 4.00)2.00 
(1.50, 24.0)1.75 
(1.01, 3.00)2.01 
(1.01, 3.00)2.50 
(1.02, 4.01)
T1/2(h) 4.47 [PHONE_15348] [PHONE_15349] [PHONE_15350] [PHONE_15351] [PHONE_15352] [PHONE_15353] +2.60
CL/F (L/h) 250 [PHONE_15354] [PHONE_15355] [PHONE_15356] [PHONE_15357] [PHONE_15358] [PHONE_15359] +21.3
Vz/F (L) 1730 +
15102360 +
13903150 +
12702500 +
12904190 +
25701620 + 561 904 +469
Urine
Ae0-48(µg) 9.72 [PHONE_15360] [PHONE_15361] +21.3 N/C 135 [PHONE_15362] + 924 636 +600
Fe(%) 0.032 +
0.0290.032 +
0.0150.024 +
0.011N/C 0.027 +
0.0210.129 +
0.1150.064 +
0.060
CL Renal
(mL/h)50.0 [PHONE_15363] [PHONE_15364] +15.5 N/C 77.5 [PHONE_15365] [PHONE_15366] +36.5
PK parameters are prese nted to 3 significant digits, N/ C = Not Calculated
a N=5 for AUC 0-inf, T1/2, CL/F, and V z/F
b N=5 for A e0-
48, Fe, and CL renal
c T maxis presented as median (minimum, maximum)
The A e0-48, Fe, and Cl renalfor subject  (500 mg GS -0976) were missing, because this subject was unable to provide urine 
samples during the [ADDRESS_1008909]  (800 mg GS -0976) were excluded fro m the summary statistics, because the urine sample 
for the 24 -36 hour collection interval was partially spi[INVESTIGATOR_738389] (ie, calculations were based off an 
approximate urine volume)
[IP_ADDRESS]. Study  0976- 102: Multiple Ascending Dose (MAD) Study
The multiple ascending dose (MAD) stud y (Protocol Number 0976- 102) was a randomized, 
double -blind, placebo -controlled, clinical study  conducted in health y adult subjects at one study 
center in the [LOCATION_002]. Five (5) cohort s of 8 subjects (6 active and 2 placebo) were evaluated 
at the following GS -0976 doses: 50 mg BID (100 mg dail y) or placebo, 100 mg QD (100 mg 
daily ) or placebo, 100 mg BID (200 mg daily ) or placebo, 200 mg QD ( 200mg dail y) or 
placebo, or 150 mg QD (150 mg dail y) or placebo. I n each co hort, subjects received multiple 
[COMPANY_003]
[COMPANY_003]--
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 21 15 December 2016oral doses of GS -0976 or placebo BID (every  12 hours) or once dail y (QD) for 9 consecutive 
days (Day s 1 through 9), with a single oral dose of GS -[ADDRESS_1008910] 4 dose groups was full y enrolled and, overall, 24 subjects received GS-0976 and 
8 subjects received placebo. The majority  of these 32 su bjects who received GS-0976 (19/24, 
79%) and placebo (4/8, 50%) had at least 1 treatment- related AE as assessed by  [CONTACT_941] p rincipal 
investigator. The incidence of treatment -related AEs appeared to increase with higher doses and 
BID dosing of GS -0976: 50% of subjects at 50 mg BID, 62.5% at 100 mg QD, 75% at 200 mg 
QD, and 100% at [ADDRESS_1008911] in the 200 mg QD cohort discontinued due to an AE 
on study  Day  7 for Grade 4 elevated trigl ycerides (TG) . No deaths or SAEs were reported. 
The most frequentl y reported TEAEs were gastrointestinal disorders and involved nausea 
(33% of all subjects who received GS -0976 vs. 0% of all subjects who received placebo), 
abdominal distension (25% GS -0976 vs. 13% placebo), constipation 
(21% GS-0976 vs.13% placebo), diar rhea (21% GS -0976 vs. 0% placebo), and vomiting 
(13% GS-0976 vs. 0% placebo). In addition, TEAEs of increased blood trigl ycerides were 
reported (25% GS-0976 vs. 0% placebo) and involved Grade 3 events in 5 subjects (3 subjects in 
the 100 mg BID cohort and 2 subjects in the 50 mg BID cohort), and a Grade [ADDRESS_1008912] 
in the 200 mg QD cohort (discontinued treatment).
There were no clinicall y important treatment- related or dose -related trends in vital signs, ECG, 
or phy sical examination assessments in this study .
Preliminary  single (Day  1) and (Day  10) multiple dose PK parameters for GS- [ADDRESS_1008913] observed in study 0976 -101.  The mean T1/2of GS -0976 ranged from 
3.5-10.3 hours with higher variability  contributing to the higher mean estimates from Day  10 in 
the 50 mg BID and 100 mg QD cohorts.  Mean plasma NDI -011535 exposure was < 10% of 
GS-
0976 plasma exposure, based on MPR for AUC and C max.  The PK profile of NDI -011535 
was consistent with the PK profile of GS-0976, as seen by  [CONTACT_738403]  1 and Day  10 as well as across the doses evaluated. NDI -011535 exhibits formation 
rate limite d kinetics as the mean T 1/2of NDI -011535 was consistent with that observed for 
GS-0976.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 22 15 December 2016Table 1-2. Summary of Single and Multiple Dose Pharmacokinetic Parameters 
of GS -0976 Following Administration of 50 mg BID, 100 mg QD, 
100mg BID, or 200 mg QD GS -0976 Under Fed Conditions
Plasm a PK Param eter
Mean +SDGS-0976 Dose
50 m g BID Fed 
(N=6)100 m g QD Fed 
(N=6)100 m g BID Fed 
(N=6)200 m g QD Fed 
(N=6)
Day 1
AUC 0-12or24 (ng*h/mL) 143 [PHONE_15367] [PHONE_15368] [PHONE_15369] +221
AUC 0-inf(ng*h/mL) 178 +40.7a278 +110a671b979 +286a
Cmax(ng/mL) 41.3 [PHONE_15370] [PHONE_15371] [PHONE_15372] +68.4
Tmax(h)c2.50 (1.50, 3.02) 3.50 (1.00, 6.00) 5.02 (3.00, 8.00) 5.00 (2.00, 6.00)
T1/2(h) 3.50 +1.63a4.33 [PHONE_15373]a5.58b5.86 +3.59a
CL/F (L/h) 292 +61.6a403 +139a149b219 +64.0a
Vz/F (L) 1350 + 333a2560 [PHONE_15374]a1120b1710 + 720a
Day 10
AUC 0-tau(ng*h/mL) 305 [PHONE_15375] [PHONE_15376] [PHONE_15377] + 573a
RAUC 2.13 [PHONE_15378] [PHONE_15379] [PHONE_15380] [PHONE_15381]a
Cmax(ng/mL) 49.4 [PHONE_15382] [PHONE_15383] [PHONE_15384] +86.6a
Cave(ng/mL) 25.4 [PHONE_15385] [PHONE_15386] [PHONE_15387] +23.9a
Ctrough (ng/mL) 12.4 [PHONE_15388] [PHONE_15389] [PHONE_15390] +42.9a
Tmax(h)c4.01 (2.05, 8.00) 3.01 (2.00, 12.0) 6.00 (2.00, 6.00) 4.00 (1.50, 6.00)a
T1/2(h) 10.3 [PHONE_15391] [PHONE_15392] [PHONE_15393] [PHONE_15394]a
CL ss/F (L/h) 173 [PHONE_15395] [PHONE_15396] [PHONE_15397] +46.4a
PK parameters are presented to 3 significant digits
RAUC = Ratio of Day 10 AUC 0-tau/ Day 1 AUC 0-t
a N=5
b N=1
c T maxis presented as median (minimum, maximum)
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 23 15 December 2016Table 1-3. Summary of Single and Multiple Dose Pharmacokinetic Parameters 
of ND -011535 Following Administration of 50 mg BID, 100 mg QD, 
100mg BID, or 200 mg QD GS -0976 Under Fed Conditions
Plasm a PK Param eter 
Mean +SDGS-0976 Dose
50 m g BID Fed 
(N=6)100 m g QD Fed 
(N=6)100 m g BID Fed 
(N=6)200 m g QD Fed 
(N=6)
Day 1
AUC 0-12or24 (ng*h/mL) 11.6 +3.57a23.7 [PHONE_15398]b29.9 +15.1a78.8 +43.3c
MPR AUC 0.064 + 0.022c0.042d0.063 + 0.027a0.0636 [PHONE_15399]c
Cmax(ng/mL) 3.14 [PHONE_15400] [PHONE_15401] [PHONE_15402] +6.66
MPR C max 0.057 + 0.013 0.051 + 0.023 0.054 + 0.028 0.048 + 0.020
Tmax(h)e2.50 (1.50, 302) 3.50 (1.50, 6.00) 6.00 (4.00, 11.9) 6.00 (4.00, 6.00)
T1/2(h) 5.13 +2.93a3.59 [PHONE_15403]bN/C 7.55 +2.06c
Day 10
AUC 0-tau(ng*h/mL) 28.5 [PHONE_15404] +22.6f67.0 [PHONE_15405] +74.3a
RAUC 2.49 +0.32a2.50 [PHONE_15406]b1.93 [PHONE_15407]a2.41 +1.03f
MPR AUC 0.072 + 0.013 0.073 + 0.015 N=3 0.050 + 0.020 0.052 + 0.016a
Cmax(ng/mL) 4.92 [PHONE_15408] [PHONE_15409] [PHONE_15410] +5.33a
Cave(ng/mL) 2.37 [PHONE_15411] [PHONE_15412]f3.95 [PHONE_15413] +3.09a
MPR C max 0.075 + 0.014 0.057 + 0.028 0.046 + 0.019 0.051 + 0.02a
Ctrough (ng/mL) 1.20 [PHONE_15414] + 0.078b3.76 [PHONE_15415] +3.18c
Tmax(h)e3.50 (2.05, 6.00) 4.51 (2.00, 6.02) 6.00 (1.50, 6.04) 6.00 (3.00, 6.00)a
T1/2(h) 4.61 +1.30a6.00 [PHONE_15416]b5.67 +0.40b5.14 +2.14f
PK parameters are presented to 3 significant digits
RAUC = Ratio of Day 10 AUC 0-tau/ Day 1 AUC 0-t
MPR = Metabolite to Parent Ratio corrected for molecular weight
N/C = Not Calculated
a N=5
b N=2
c N=4
d N=1
e T maxand T 1/2are presented as median (minimum, maximum)
f N=3
[IP_ADDRESS]. Study  0976- 103: Single Ascending Dose Pharmacody namic Study
The single ascending dose PD study  (Study  0976- 103) was a two -period, two -treatment, 
crossover, randomized, double
-blind, study  to determine the P D activity  on fractional DNL of a 
single oral dose of 20, 50, or 200 mg of GS-0976 compare d to placebo in 3 cohorts of 10 adult 
male subjects who were overweight and/or obese, but otherwise health y, at each dose level (total 
30 subjects). Subjects were ran domized in Period 1 to receive a single oral dose of either 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 24 15 December 2016GS-0976 or matched placebo followed b y a washout and administration of the opposite study  
medication in Period 2. 
The objectives of the study  were to assess the following after a single oral dose of GS-0976 in 
overweight and/or obese, but otherwise health y, adult male subjects: PD effects of GS-0976 on 
fractional DNL, safety  and tolerability  of GS -0976, correlation of PK and PD effects, and PK 
parameters. 
Fractional DNL was evaluated b y utilizing a qualified method that measured the appearance of 
de novo sy nthesis of palmitate in very -low density  lipoproteins (VLDL) in response to oral 
fructose using [13C]acetate inc orporation into palmitate and mass isotopomer distribution 
analysis (M IDA). Review of the data demonstrated mean inhibition of fractional DNL (71%, 
87%, and 98% by [CONTACT_12265]) by  [CONTACT_10827]-0976 at 20, 50, and 200 mg, respectivel y, compared to matched 
placebo.
Atotal of 41 TEAEs were experienced b y 15 (52%) subjects following administration of 
GS-0976 ( 28 considered possibly  related); 22 TEAEs were experienced by  12 (40%) pooled 
placebo subjects (17 considered possibly  related), and 4 TEAEs were experienced by  4 (13%) 
subjects following the [13C]acetate infusion. Gastrointestinal events including diarrhea (11/29, 
38% GS -0976 vs. 9/30 ,30% placebo) and flatulence ( 5/29, 17% GS -0976 vs. 3/30, 
10% placebo) were the most common TEAEs following both active and placebo treatme nts. The 
incidence of treatment emergent AEs did not increase with r ising GS -[ADDRESS_1008914] TEAEs in the study were of Grade 1 severit y (39/41, 95 %) and were resolved b y stud y 
completion. Three subjects experienced 4 TEAEs of Grade 2 severity  including headache and 
nausea (placebo), arthralgia (GS -0976 20 mg ), and dy spepsia (GS -0976 20 mg ). No deaths or 
SAEs were reported. 
Overall, no clinicall y important trends in changes over time were noted in the laboratory  results 
for GS -0976 active groups co mpared to placebo. 
1.3. Rationale for the Current Study
Current evidence suggests that NASH is a consequence of the metabolic s yndrome and 
lipotoxicity  in the steatotic liver, which sets off an inflammatory response with subsequent 
activation of hepatic stella te cells and fibrogenesis. A key  finding in patients with NASH is 
upregulation of the hepatic sy nthesis of fatty  acids and trigl ycerides, referred to as de novo 
lipogenesis (DNL). Enhanced DNL in NASH occurs despi[INVESTIGATOR_738390] {Lambert 2014 }.
DNL -derived fatt y acids and their b yproducts (e.g. diacy lglycerol, l ysophosphatidic acid, and 
eicosanoids) represent important signaling mediators that drive the lipotoxicity  and inflammation 
characteristic of NASH 
{Neuschwander -Tetri 2010 }. The first and rate -limiting step in DNL is 
theconversion of acet yl-coA to malony l
-coA by [CONTACT_738404]-coA carbox ylase (ACC). ACC exists as 
two isoforms (ACC1 and ACC2). Whereas ACC1 is a cy tosolic enzy me present in lipogenic 
tissues ( e.g. liver and adipose), ACC2 is a mitochondria -associated enz ymepresent in oxidative 
tissues ( e.g. liver, heart , and skeletal muscle) {Bianchi 1990 , Kim 1997}. Inhibition of ACC1 
reduces DNL in lipogenic tissues while inhibition of ACC2 in oxidative tissues enhances 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 25 15 December 2016mitochondrial fatty  acid oxidation {Harwood 2005 }.Due to this unique posit ion in intermediary  
metabolism {Harwood 2005, Tong 2006 },pharmacologic inhibition of ACC isan attractive 
strategy  for limiting fatty acid sy nthesis while simultaneously  stimulating fatty  acid oxidation.
GS-0976 is a highl y potent and selective alloste ric inhibitor of ACC1 and ACC2. 
Pharmacod ynamic studies indicate that GS -
0976 reduces DNL, hepatic steatosis, inflammatory  
mediators, and fibrosis in preclinical models of liver disease {Harriman 2016 }. In addition,
GS-0976 improve smetabolic parameters (e.g. plasma trigl ycerides and free fatt y acids, insulin, 
and leptin sensitivity ) in high fat and high sucrose diet -induced obesit y models. I n total, these 
studies confirm the potential for GS- [ADDRESS_1008915] important histologic endpoints in NASH and 
alsoameliorate the metabolic dy sfunction frequently  observed in these patients. Moreover, the 
liver-directed biodistribution of GS -
0976 e nsures that pharmacological effects are focused on the 
key target tissue for NASH and is anticipated to minimize effects outside of the liver.
In summary , the totality  of the preclinical and clinical evidence, in addition to the large unmet 
medical need an d the lack of existing therapi[INVESTIGATOR_014], suggests that the evaluation of GS -0976 in 
subjects with NASH , as proposed in the current study , is of merit.
1.3.1. Rationale for th is Study
This Phase 2 study  has been designed as a multicenter, randomized, double -blind, 
placeb o-controlled study  evaluating the safet y and efficacy of GS -0976 for 12 weeks in subjects 
with NASH. Approximately  125 NASH subjects without cirrhosis will be randomized in a 
2:2:[ADDRESS_1008916] a clinical diagnosis of NAFLD andevidence of
NASH histologicall y or based on magnetic resonance imaging; specifically, ≥
8%hepatic 
steatosis on MRI -PDFF {Bannas 2015 }
and increased liver stiffness on MRE ( ≥ 2.5 kPa) {Park 
2016}. Previous studies have shown that patients with NAFLD and increased liver stiffness b y 
MRE have a high probability  of NASH on liver biopsy . For example, Park et al. reported that an 
MRE liver stiffness cut -off of 
≥ 2.53 kPa was 64% sensitive, 68% specifi c, and had an area 
under the receiver operating characteristic curve (AUROC) of 0.
70and positive predictive value 
of 87% for the differentiation of simple steatosis from NASH on biopsy . Moreover, in this cohort 
of 104 patients, Park et al. demonstrated that a liver stiffness by  [CONTACT_232761] ≥ 2.[ADDRESS_1008917] stage 1 fibrosis (AUROC 0.82). Based on these criteria, 
subjects enrolled in this study  have a high probability  of NASH with fibrosis, a population with a 
large unmet me dical need {Loomba 2014 }. Since the safet y and PK of GS -[ADDRESS_1008918] been developed in order to exclu de 
cirrhotic subjects based on a validated serum marker for fibrosis (FibroTest®) and historical 
clinical, histological, and imaging data {Ratziu 2006 }.
The primary  endpoint of this study
 will be the safety and tolerability  of GS -0976. I n addition, the 
biological activity  of GS -0976 will be determined based on endpoints including routine liver 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 26 15 December 2016biochemistry  (e.g. ALT and GGT); noninvasive serum markers of liver injury  (e.g. serum 
CK-18, FibroTest®and ELF™ Test ); and imaging -based methods for quantify ing hepatic 
steatosis (MRI -PDFF) and fibrosis (MRE and FibroS can®). An important endpoint of interest is 
the proportion of subjects achieving ≥ 30% reduction in steatosis as assessed by  [CONTACT_9268] -PDFF. 
This level of reduction has been associated with a significant improvement in NASH histology 
(≥ 2-point reduction in NAFLD Activity  Score) { Patel 2015}. Based on preclinical and clinical
data, 
a treatment duration of 12 weeks with GS -0976 is expected to be sufficient to lead to 
meaningful improvements in hepatic steatosis on MRI -PDFF and liver biochemistry . Liver 
histology  has not been included as an endpoint because it is not feasible to repeat this invasive 
procedure over a 12 -week study . In addition to these liver -related endpoints, the effects of 
GS-0976 on carboh ydrate and lipid metabolism (e.g. with glucose, insulin, free fatt y acids, 
apolipoproteins, lipid profiles, and metabolites) will be closely  monitored in light of the 
mechanism of action of GS -0976 and the importance of metabolic d ysfunction in contributing to 
the morbidity  and mortality  (e.g. cardi ovascular) of subjects with NASH .
The doses of GS -0976 chosen for evaluation in this study , 5 and 20 mg QD for 12 weeks, are 
supported by  [CONTACT_395494] , tolerability  and effects of GS -0976 on DNL from studies 0976 -101, 
0976- 102, and 0976 -103. As described in Section 1.2.5 , single doses of GS -0976 up to 1000 mg 
or multiple daily doses (10 day s) up to 200 m g were administered safel y to healthy subjects in 
these studies. Moreover, a single dose of 20 mg resulted in a mean inhibition of fractional DNL 
of 71%. This level of DNL is postulated to be sufficient to achieve meaningful reductions in 
hepatic steatosis and lipid- derived inflammatory  mediators that contribute to the pathogenesis of 
NASH . The four -fold GS -[ADDRESS_1008919] been conducted in 
rats and dogs at exposure margins multiple folds above the expected clinical exposure. Based on 
preliminary  data from studies 0976- 101 (Section [IP_ADDRESS] ) and 0976-102 (Section [IP_ADDRESS]), 
GS-0976 exposures in this study  are expected to remain > 15 to23-fold lower than the GS - 0976 
exposures observed at the NOAELs in the 13 -week rat and dog studies, respectivel y.
1.4. Risk/Benefit Assessment for the Study
This study  will provi de information on the safety  and efficacy  of GS -[ADDRESS_1008920] been observed in pre-clinical and/or clinical studies of 
ACC in hibition. I mprovements in liver biochemistry  and hepatic fibrogenesis would be expected 
to ensue based on these effects.
To date, [ADDRESS_1008921] received GS -0976 in Phase 1 studies in single doses up to 1000 mg or 
multiple daily  doses (10 day s) up to 200 mg. In general, treatment emergent adverse events 
(TEAEs) were mild to moderate with the predominant toxicities being gastrointestinal 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 27 15 December 2016(e.g. nausea, flatulence, diarrhea, constipation) in nature (see Section 1.2.5). Asy mptomatic, 
Grade [ADDRESS_1008922] clinical experience with GS -0976, the risk/benefit is positive and supports the cont inued 
evaluation of GS -0976 in this patient population. Data from this study  will support the 
development of GS -0976 for the treatment of this condition.
1.5. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 28 15 December [ZIP_CODE]. OBJECTIVES
The primary objective of this study  is as follows:
To evaluate the safet y and tolerability  of GS -0976 in subjects with NASH .
The exploratory objectives of this study  are as follows: 
CCI
GS-[ADDRESS_1008923] with history  of decompensated liver disease, including ascites, 
hepatic encephalopath y or var iceal bleeding will be ineligible.
The overall study  design is presented graphicall y in Figure 3-1.
Figure 3
-1. Overall Study Design
3.2.
Treatment Plan and Regimen
Subjects meeting the study ’s entry  criteria will be randomly  assigned in a 2:2:1 ratio to 1 of 3 
different treatment groups , A, B, and C, as shown in Figure 3-1. Randomization will be stratified 
by [CONTACT_738405] , use of 
medication for i ndication of 
diabetes mellitus, or based on S creening lab values if previousl y 
undiagnosed (i .e., hemoglobin A1c ≥ 6.5% OR fasting plasma glucose ≥ 126mg/dL).
Study  drug swill b e administered for a total of 12 weeks from the 
Baseline/Day 1visit. Dosage 
and administration of the study  drug sand reference product are described in Section 5.3.
Group A (n=S0) 
GS-0976 5 mg+ 5 mg-PTM + 2 x 10 mg-PTM 
orally once daily 
C 0 
bO 
C 1ii Group B (n=S0) C N ... a, E 2 x GS-0976 10 mg+ 2 x 5 mg-PTM a, .,,. 
0 ... orally once daily u "'C VI C 
(0 
0::: 
Group C (n=25) 
2 x 5 mg-PTM + 2 x 10 mg-PTM 
orally once daily 
6Weeks 12W eeks .... 
C 
QI 
E 
1ii 
QI 
r+ ... I--0 
"'C 
C 
LU 
r+ > "'C 
::J 
ti -0 
"'C 
C 
LIJ 
........ 
a. 
::J 
-15 
LL 
4 
Weeks 
GS-0976 
Protoco l GS-US-426 -3989 
[COMPANY_009] Sciences , Inc. 
3.3. 
3.3.1. Bio marker Testing 
Biomarker Sample s to Addre ss the Study Objective s Final 
Amendment 1 
Biological spec imens wi ll be collec ted in this study as per the study procedures table to evaluate 
the association of explorato 1 y syste mic and/o r tissue sp ecific bioma rkers with study drugs 
respo nse, pathway markers, inclu ding efficacy and/o r adverse events and to increase knowledge 
and understand ing of the bi ology of NAS H or related diseases such as liver fibrosis, and 
inflammato 1 y diseases and/or the validation of a companion diagnostic for GS-[ADDRESS_1008924] ively all tests that will be done on the 
specime ns prov ided. It may be modified during or after the end of the study to remove tests no 
longer indicated and/o r to add new tests based upon the grow ing state of aii knowledge. Samples 
will be will be stored for up to [ADDRESS_1008925] meet all of the following inclusion criteria to be eligible for participation in this 
study .
1) Males and females between 18-75 years of age; inclusive based on the date of the Screening 
visit;
2)Willing and able to gi ve informed consent prior to any  study  specific procedures being 
performed;
3)Meets the following conditions:
a)A clinical diagnosis of NAFLD with imaging 
or a liver biopsy  documenting fatty  liver 
within two y ears prior to Screening (if necessary ,an ultrasound may  be performed during 
Screening to confirm NAFLD ), and 
b)Screening MRI -PDFF with ≥ 8% steatosis , and
c)Screening MRE with liver stiffness ≥ 2.5 kPa.  
Note: criterion 3a. must be met before evaluating criteria 3b. and 3c.
OR
d)A historical l iver biopsy  within 12 months of Screening consistent with NASH (defined 
as the presence of steatosis
, lobular inflammation, and hepatocellular ballooning) with 
fibrosis , but not cirrhosis, and
e)No documented weight loss > 5% between the date of the liver biops y and Screening.
4)
Platelet count ≥ 100,000/mm3
5)Creatinine Clearance (CLcr ) as calculated by  [CONTACT_16424] -Gault equation ≥ 60 ml/min
6)Female subjects of childbearing potential (see definition in 
Appendix 3) must have a negative 
serum pregnancy  test prior to starting stud y treatment;
7)
All female subjects of childbearing potential who engage in heterosexual intercourse must 
agree to use a highl y effective method of contraception during intercourse from the 
Screening visit throughout the study  period and for [ADDRESS_1008926] dose of study  
drugs (see Appendix 3for details);
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 32 15 December [ZIP_CODE])Male subjects are required to use barrier contraception (condom plus spermicide) during 
intercourse from the Screening through the stud y completion and for [ADDRESS_1008927] dose of study  drugs (see Appendix 3for details); 
9)Male subjects must refrain from sperm donation from Screening through at least [ADDRESS_1008928] dose of study  drugs.
10)Female subjects must refrain from egg donation or harvest for [ADDRESS_1008929] dose of stud y 
drugs.
11)Willing and able to comply  with scheduled visits, drug administration plan, laboratory  tests, 
other study  procedures, and study  restrictions.
12)Must be able to read and complete Qualit y of Life questionnaires independently.
4.3. Exclusion Criteria
Subjects who meet 
anyof the following exclusi on criteria will not be randomized in this study .
1) Pregnant or lactating females; lactating females must agree to discontinue nursing before the 
study  drugs are administered;
2)ALT > 5 x UL N;
3) O ther ca uses of liver disease including autoimmune, viral, and alcoholic liver disease;
4)Cirrhosis of the liver as defined b y any of the following:
a)Cirrhosis on historical liver biopsy (e.g. NASH CRN classification stage 4 or equivalent);
b)Evidence of cirrhosis on liver imaging (e.g. ultrasound, CT, or MRI ) including a nodular 
liver surface, splenomegaly , or portal venous collaterals;
c)Prior history  of decompensated liver disease, including ascites, hepatic encephalopath y or 
variceal bleeding;
d)Screening FibroSURE/Fib
roTest®≥ 0.75, unless a historical liver biopsy  within 
12months of Screening does not reveal cirrhosis . In patients with Gilbert’s sy ndrome or 
hemoly sis, FibroSURE/FibroTest®will be cal culated using direct bilirubin instead of 
total bilirubin.
5)History  of liver transplant ation;
6)Weight reduction surgery in the 
2 years prior to Screening or planned during the study  
(weight reduction surgery is disallowed during the study );
7)History  of intestinal resection or malabsorptive condition that may  limit the absorption of 
GS-0976. Prior cholecy stectomy  and appendectomy  are permitted
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 33 15 December [ZIP_CODE])BMI < 18 kg/m2;
9)INR > 1.2, unless on anticoagulant therapy ;
10)Total bilirubin > [ADDRESS_1008930], except with diagnosis of Gilbert’s s yndrome;
11)Chronic hepatitis B (HBsAg positive);
12)Chronic hepatitis C (HCV Ab and HCV RNA positive) . Subjects cured of HCV infection less 
than 
2years prior to the Screening visit are not eligible.
13)HIV Ab positive;
14)Alcohol consumption greater than 21 oz/week for males or 14 oz/week for females 
(1oz/ 30mL  of alcohol is present in 1 12oz/3 60mL beer, 1 4oz/12 0mL  glass of wine, and a 
1oz/30mL measure of 40% proof alcohol) ;
15)
Positive urine screen for amphetamines, cocaine or opia tes (i.e. heroin, morphine) at 
Screening. Subjects on stable methadone or buprenorphine mai ntenance treatment for at least 
6months prior to S creening may  be included in the study . Subjects with a positive urine drug 
screen due to prescription opi[INVESTIGATOR_2480]-based medication are eligible if the prescription and 
diagnosis are reviewed and approved b y the investigator ;
16)Unstable cardiovascular disease as defined b y any of the following:
a)Unstable angina within 6 months prior to Screening
b)Myocardial infarction, coronary  artery  by[CONTACT_550241] 6 months prior to Screening
c)Transient ischemic attack or cerebrovascular accident within 6 months prior to Screening
d)Obstructive valvular heart disease or h ypertrophic cardiom yopath y
e)Congestive heart failure;
17)Use of prohibited concomitant medications as described in Section 5.4
18)History  of a ma lignancy  within 5 y ears prior to S creening with the following exceptions:
a)Adequatel y treated carcinoma in situ of the cervix
b)Adequatel y treated basal or squamous cell cancer or other localized non -melanoma skin 
cancer;
19)Any laboratory  abnormality  or condition that, in the investigator’s opi[INVESTIGATOR_1649], could adversely  
affect the safet y of the subject or impair the assessment of study results;
20)Participation in another investigational stud y of a drug or device within 28 day sprior or 
within 5 half -lives of the prior investigational agent (whichever is longer) prior to S creening;
21)Concurrent participation in another therapeutic clinical study ;
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 34 15 December 201622)Known hy persensitivity  to GS -0976, the metabolites, or formulation excipi[INVESTIGATOR_841];
23)Presence of an y condition that could, in th e opi[INVESTIGATOR_871], compromise the 
subject’s ability  to participate in the study , such as history  of substance abuse or a ps ychiatric 
(including an y subjects with a psy chiatric hospi[INVESTIGATOR_550226] 
2 years prior to S creening) or medical condition;
24)Unavailable for follow -up assessment or concern for subject’s compliance with the protocol 
procedures;
25)Contraindications or inability  to complete MRI scanning (e.g. presence of permanent 
pacemakers, implanted cardiac devices , weight r estrictions, etc.).
Subjects with laboratory  abnormalities outside of the above parameters may be approved for 
inclusion in the trial with app roval from the Medical Monitor.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 35 15 December [ZIP_CODE]. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
This is a randomized, double -blind, p lacebo -controlled study . Subjects meeting the study  entry  
criteria will be randomly assigned in a 2:2:1 ratio to 1 of 3 different treatment group as described 
in Section 5.3.
5.1. Randomization, Blinding and Treatment Codes
An Interactive Web Response Sy stem (I WRS) will be used for centralized randomization and 
treatment assignment. Randomization will be stratified by  [CONTACT_738406] , use of medication for indication of diabetes mellitus, 
or based on 
Screening lab values if previousl y undiagnosed (ie, hemoglobin A1c ≥ 6.5% OR 
fasting plasma glucose ≥ 126 mg/dL).
Investigative site personnel will obtain the subject’s identification number and study  drug 
assignment from the I WRS. Subjects and all personnel directl y involved in the conduct of the 
study  will be blinded to treatment assignment.
Study  drug swill be dispensed by  [CONTACT_569944], or designee, in a blinded fashion to the 
subjects.
5.1.1. Procedures for Breaking Treatment Codes
In the event of a me dical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator (or designee)  may  obtain treatment assignment directl y from the 
IWRS sy stem for that subject (refer to Study  Reference Binder for IWRS unblinding
instructions). [COMPANY_009] recommends but does not require that the investigator contact [CONTACT_738407]. Treatment assignment should remain blinded unless 
that knowledge is necessary  to determine subject emergency  medical care. The rationale for 
unblinding must be clearly explained in source documentation and on the electronic case report 
form (eCRF), along with the date on which the treatment assignment was obtained. The 
investigator is requested to contact [CONTACT_738408] y treatment 
unblinding.
Blinding of stud y treatment is critical to the integrity  of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued. All subjects will be followed until study  completion unless consent to do 
so is specificall y withdrawn by [CONTACT_423].
[COMPANY_009] Drug Safet y and Public Health (DSPH) may independentl y unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (S[LOCATION_003]Rs).
GS-[ADDRESS_1008931] gelatin capsules containing 5 mg of GS-0976. In 
addition to the active ingredient, GS- 0976 capsules contain the following inactive ingredients: 
lactose monohy drate, stearoy l polyoxylglycerides and croscarmellose sodium ,which are 
common pharmaceutica l excipi[INVESTIGATOR_840].
Placebo- to-match ( 10 mg -PTM and 5 mg -PTM) GS-0976 capsules are identical in size, shape, 
color and appearance to their corresponding strengths of active GS-0976 capsules. PTM 
GS-0976 capsules contain lactose monohy drate.
5.2.2. Packaging and Labeling
GS-0976 capsules and PTM GS-0976 are packaged in white, high density  poly ethylene (HDPE) 
bottles. Each bottle contains 30 capsules .  Each bottle is enclosed with a white, continuous 
thread, child- resistant poly propy lene screw cap with an induction -sealed and aluminum -faced 
liner.
Study  drugs to be distributed to centers in the US shall be labeled to meet applicable 
requirements of the [LOCATION_002] Food and Drug Administration (FDA) and/or other local 
regulations.
5.2.3. Storage and Handling
GS-0976 and P TM GS -0976 should be stored at controlled room temperature of 25 °C (77 °F); 
excursions are permitted between 15°C and 30°C (59°F and 86°F).  Storage conditions are 
specified on the label.  Until dispensed to the subjects, all bottles of study  drugs should be stored 
in a securely  locked area, accessible only  to authorized site personnel. 
To ensure the stabilit y and prop er identification, study  drugs should not be stored in a container 
other than the container in which they  were su
pplied. 
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact [CONTACT_10850] . Appropriate precautions should be followed to avoid direct 
eye contact [CONTACT_90265].
5.3. Dosage and Administration of GS -0976/PTM GS -
0976 
GS-
0976 capsules will be provided b y [COMPANY_009] Sciences.  Subjects will take 4capsules of 
GS-0976 (5 mg, 5 mg -PTM, 10 mg, or 10 mg -PTM) once dail y at approximately  the same time 
each morning.  Study  drugs should be swallowed whole with water and may  be ta ken with or 
without food.  A dose will be considered missed if the subject cannot take the dose within 
[ADDRESS_1008932] should take their 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 37 15 December 2016next dose at the regular dosing time. Study  drug dosing and administration will occur as follows, 
based on treatment group randomization:
Treatment Group A: GS -0976 5 mg (1 x 5 mg capsule + 1 x 5 mg -PTM 
capsule + 2 x 10 mg-PTM capsules) administered orally  once dail y;
Treatment Group B: GS -0976 20 mg (2 x 10 mg capsules + 2 x 5 mg -PTM capsules) 
administered orall y once daily ;
Treatment Group C: GS -0976 Placebo (2 x 5 mg -PTM capsules + 2 x 10 mg -PTM capsules) 
administered orall y once daily .
5.4. Prior and Concomitant Medications
All concomitant medication will be re corded in the source documents and eCRFs.  This includes 
concomitant medications taken within 30 day s prior to S creening and an y taken during the stud y 
to the end of the follow -up period.
The following medications are prohibited from 28 day s prior to Basel ine/Day [ADDRESS_1008933] dose of study  drugs:
Hematologic stimulating agents (e.g. ery thropoiesis- stimulating agents (ESAs); granulocy te 
colony  stimulating factor (GCSF); thrombopoietin (TPO) mimetics)
Chronic sy stemic immunosuppre ssants including, but not limited to, corticosteroids 
(prednisone equivalent of > 10 mg/day for > 2 weeks), azathioprine, or monoclonal 
antibodies (eg, infliximab) . Use for ≤ 2 weeks total is allowed.
Investigational agents or devices for an y indication
Concomitant use of certain medications or herbal/natural supplements (inhibitors or inducers 
of drug transporters P-gp, or OATP1B3 or 1B3, or substrates of CYP3A which are sensitive 
to induction) with GS-0976 may result in PK interactions resulting in increa ses or decreases 
in exposure of GS-0976 or concomitant medications. Examples of representative medications 
which are prohibited from 28 days prior to 
Baseline/Day  1through the treatment period are 
listed below in Table 5-1:
GS-[ADDRESS_1008934] of Prohibited Medications
Drug Class Agents Disallowed
Antibiotics Azithromycin, Clarithromycin, Erythromycin
AnticonvulsantsaPhenobarbital, Phenytoin, Carbamazepi[INVESTIGATOR_050], Oxcarbazepi[INVESTIGATOR_122009], Ketoconazole
AntimycobacterialsaRifamycins, Isoniazid
Cardiac Medications Amiodarone, Digoxin, Dronedarone, Felodipi[INVESTIGATOR_050], Verapamil, 
Quinidine, Ranolazine, Bosentan, Olmesartan, Telmisartan, 
Valsartan
Herbal/Natural SupplementsaSt. John’s Wort, Echinaccea. Milk thistle (i.e. silymarin), Chinese 
herb sho- saiko -to (or Xiao -Shai-Hu-Tang)
Selective Serotonin Reuptake Inhibitors Fluvoxamine
Other Gemfibrozil, Modafinil
a May result in a decrease in the concentrations of study drugs.
Medications for disease conditions excluded from the protocol (e.g., HIV -1, HBV, or HCV
infection, active cancer, transplantation) 
are not listed under this Concomitant Medication 
section and are disallowed in the study .
5.5. Accountability for GS -0976/PTM GS -0976
The investigator or designee (e .
g., pharmacist) is responsible for ensuring adequate 
accountability  of all used and unused study  drug bottles. This includes acknowledgement of 
receipt of each shipment of study  drug (quantity  and condition), subject 
dispensing records, and 
returned or destro yed study product. All used and unused study drug bottles dispensed to 
subjects must be returned to the site.
Study  drug accountability  records will be provided to each study  site to:
Record the date received and q uantity  of study  drug bottles
Record the date, subject number, subject initials, and the study  drug bottle number dispensed
Record the date, quantity of used and unused study drug returned, along with the initials of 
the person recording the information.
5.5.1. Investigational Medicinal Product Return or Disposal
Refer to Section 9.1.[ADDRESS_1008935] Research Organization (CR O).  
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the investigator to ensure that subjects are eligible to participate in the 
study  prior to enrollment and throughout the study . 
Documentation of the personally  signed and dated informed consent of each subject, using the 
study -specific ICF, is required before initiating the S creening process.
After written informed consent has been obtained and eligibility  to participate establishe d, 
investigative site personnel will obtain the subject’s identification number and study  drug 
assignment from the interactive web response s ystem (I WRS).
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened within 6 weeks prior to randomization to determine eligibility  for 
participation in the study . The Screening period may  be extended under special circumstances 
with the explicit approval of the [COMPANY_009] Medical Monitor.
Subjects who previously  failed screening in GS -US-426- 3989 can be re -screened in the 
following situations:
Previously  screen failed due to a low MRE or MRI -PDFF measurement, but 
have an 
MRE ≥2.5 kPa and MRI -PDFF ≥8% within 6 months of prior Screening/Re -screening .
Previously  screen failed due to a low MRE or MRI -PDFF measurement and have a historical 
liver biopsy  within 12 months of Screening/Re -screening that is consistent with NASH 
(defined as the presence of steatosis, hepatocellular ballooning, and lobular inflammation) 
with fibrosis, but not cirrhosis. 
Previously  screen failed due to a FibroSURE/FibroTest®≥ 0.75 in whom Gilbert’s sy ndrome 
or hemoly sis is present ; a repeat FibroSURE/FibroTest®calculated using direct bilirubin 
instead of total bilirubin will be used to determine eligibility . 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 40 15 December 2016Previously  screen failed d ue to a FibroSURE/FibroTest®≥ 0.75 and with a historical liver 
biopsy  within 12 months of Screening that does not reveal cirrhosis; FibroSure/Fibrotest 
score will not be used to determine eligibility .
If MRE and MRI -PDFF were performed within [ADDRESS_1008936] be repeated. A historical MRE and MRI -PDFF within 
6months of screening in another [COMPANY_009] stud y (i.e. GS -US-384- 3914, GS -US- 402-1852) may  be 
used to determine eligibility  into this study . All other screening procedures must be repeated and 
meet eligibility  criteria.
Screening labs m ay be repeated within the S creening period, prior to administration of study  
drugsto rule out laboratory  error, if any . This will be done at the discretion of the investigator .
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Screening visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
The following will be performed and documented at Screening:
Obtain written informed consent before initiation of an y Screening pr ocedures
Review and record whether the subject meets inclusion and exclusion criteria
Obtain S creening number from I WRS
Obtain medical history
Complete phy sical examination
Record vital signs, bod y weight, and height
Obtain blood samples for:
Chemistry
Hematology  
Coagulation Panel 
Hemoglobin A1c
HIV-1, HBV and HCV s erology (if HCV Ab positive, reflex to HCV RNA.)
Serum pregnancy  test (only  for female subjects of child bearing potential - see
Appendix 3.)
GS-0976 
Protoco l GS-US-426 -3989 
[COMPANY_009] Sciences , Inc. 
• Conduct standa rd 12-Lead ECG 
• P erfo1m ultraso und (if necessaiy) for confnmat ion of NAF LD 
• Perfo1m MRE and MRI- PDFF 
• Review any historical liver biopsy results, if available. Final 
Amendment 1 
• Ur ine diug screen for amphetamines, cocaine and opi[INVESTIGATOR_858] (i.e., heroin , morphine) 
• Reco rd all concomita nt medicatio ns th at the su bject has taken within 30 days prior to 
Scree ning 
• Reco rd any serious adve rse events and a ll adverse events related to protocol mandated 
proced ures occuning after signing of the consent fo1 m . 
Subjects meet ing all of the inclusion criteria and none of the exclusion cr iteria will return to the 
clinic within [ADDRESS_1008937] all serious adverse events (SAEs), as well as any adve rse events 
related to protoco l-mandated proced ures on the adverse events electronic case repo1i fonn 
(eCRF). All other untoward medical occmTences observed during the Screening perio d, 
including exace rbatio n or changes in medical histo1y are to be captured on the medical histo1 y 
eCRF. See Sectio n 7 Adverse Events and Toxicity Management for additio nal details. 
6.3. Baseline/Day 1 Randomization and Assessments 
Subjects retmning to the clinic for randomizatio n at Base line/Day [ADDRESS_1008938] 
(no food or di·ink, except wate r), staiii ng from midnight (00:00) or eai·lier, as appropriate , on the 
evening prior to the B aseline/Day [ADDRESS_1008939] dose of study mugs . 
Randomization will be sti·atified by [CONTACT_738409]1y, use of medicatio n for indicatio n of diabetes mellitus, or based on Scree ning 
lab values if previo usly undiagnosed (ie, hemoglobin Ale~ 6.5% OR fasting plasma 
glucose~ 126 mg/dL) . 
CONFIDENTIAL Page41 15 December 2016 
GS-0976 
Protocol GS-US-426 -3989 
[COMPANY_009] Sciences , Inc. Final 
Amendment 1 
The following will be perfonned and docume nted at the Base line/Day 1 visit prior to dosing: 
• QoL Questio nnaires (SF-36 , WPA I, and CL DQ) 
Note: It is recommended that QoL questionnaires be completed prior to any study procedures 
being perfo1med and prior to the subject seeing a h ealth care prov ider. 
• Symptom driven physical examinatio n 
• Reco rd vital signs, waist circmnf erence, and body weight 
• Obta in blood samples for: 
-Chemistiy 
- H emato logy 
-Coag ulation Panel 
-Lipid Profi le 
- H emoglob in Ale 
- Bi omarke rs 
• Conduct standa rd 12-Lead ECG 
• Perfo1m FibroSca n® (if available) 
• Collect urine samples for: 
- Ur ine pregnancy test for females of child bearing potential only 
- Bi omarkers 
• Collect stool samp le for Biomarkers (see Study Refe rence Binder for instiuct ions) 
• Dispense study mugs, and provide subject with insti11ction on appropr iate dosing and 
adinin isti·ation; subject will take the Baseline/Day 1 dose of study di11gs on-site 
• Reco rd all concomita nt medicat ions th at the su bject has taken since the previo us visit 
• Reco rd any serious adve rse events and a ll adverse events occuning since the Screening visit 
CONFIDENTIAL Page42 15 December 2016 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 43 15 December 2016Subjects will return to the investigative site at Week 1 (±3 d ays) for a mandatory  safet y visit. 
Then, starting at the Week [ADDRESS_1008940] visits every  4 weeks up to the Week 12
visit.
6.4. Treatment Assessments
6.4.1. Week 1 Visit (±3 days)
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Week [ADDRESS_1008941] been completed. The study  drug sshould be taken after the 
visit.
During the Week 1 safety visit (±3 days), the subject will return to the invest igative site and the 
following will be performed and documented:
Symptom driven phy sical examination
Record vital signs, and body  weight
Obtain blood samples for:
Chemistry
Hematology
Coagulation Panel
Lipid Profile
Biomarker s
Single PK sampling
Collect urine sample for biomarkers
Record all concomitant medications that the subject has taken since the previous visit
Record an y serious adverse events and all adverse events occurring since the previous visit
Review of stud y drug dosing compliance (pi[INVESTIGATOR_738391] t)
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 44 15 December [ZIP_CODE].4.2. Week 4 Visit (±3 days)
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Week [ADDRESS_1008942] been completed. The study  drugs should be taken after the 
visit.
The following wi ll be performed and documented at this visit (±3 day s):
Symptom driven phy sical examination
Record vital signs, and body  weight
Obtain blood samples for:
Chemistry
Hematology
Coagulation Panel
Lipid Profile
Biomarker s
Single PK sampling
Collect urine samples for:
Urine pregnancy  test for females of child bearing potential only
Biomarkers
Dispense study  drug s
Record all concomitant medications that the subject has taken since the previous visit
Record an y serious adverse events and all adverse events oc curring since the previous visit
Review of stud y drug dosing compliance (pi[INVESTIGATOR_692])
6.4.3. Week 8 Visit (±3 days)
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening pr ior to the Week 8visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
GS-[ADDRESS_1008943] been completed. The study  drug s should be taken after the 
visit.
The following will be performed and documented at these visits (±3 day s):
Symptom driven phy sical examination
Record vital signs, and body  weight
Obtain blood samples for:
Chemistry
Hematol ogy
Coagulation Panel
Lipid Profile
Single PK sampling
Urine pregnancy  test for females of child bearing potential only
Dispense study  drug s
Record all concomitant medications that the subject has taken since the previous visit
Record an y serious adverse e vents and all adverse events occurring since the previous visit
Review of stud y drug dosing compliance (pi[INVESTIGATOR_692])
6.4.4. Week 12 Visit (±7days)
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Week [ADDRESS_1008944] prior to the fasted blood sample collection the next morning.
Subjects should also be instructed to HOLD their dose of study  drug son the day  of their 
Week 12 visit until all visit procedures hav e been completed. The study  drugs should be taken 
after the visit.
The following will be performed and documented at this visit (±7 day s):
QoL Questionnaires ( SF-36, WPAI , and C LDQ )
Symptom driven phy sical examination
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 46 15 December 2016Record vital signs, waist circumference, and bod y weight
Obtain blood samples for:
Chemistry
Hematology
Coagulation Panel
Lipid Profile
Hemoglobin A1c
Biomarker
Single PK sampling
Collect urine samples for:
Urine pregnancy  test for females of child bearing potential only
Biomarkers
Conduct standard 12 -Lead ECG
Perform FibroScan®(if available)
Perform MRE and MRI -PDFF
Collect stool sample for Biomarkers (see Study  Reference Binder for instructions)
Record all concomitant medications that the subject has taken since the previous visit
Record an y serious adverse events and all adverse events occurring since the previous visit
Review of stud y drug dosing compliance (pi[INVESTIGATOR_692])
6.4.5. Unscheduled Visit
Additional unscheduled assessments may  be performed at the discretion of the investigator.
Subjects returning to the clinic for an unscheduled visit should be instructed to fast (no food or 
drink, except water), starting from midnight (00 :00) or earlier, as appropriate, on the evening 
prior to the visit to ensure an approximate [ADDRESS_1008945] been completed. The stud y drugs should be 
taken after the visit.
At a minimum, the following will be performed and documented.
Symptom driven phy sical examination
Obtain blood samples for:
Chem istry
Hematology
Record bod y weight
Record all concomitant mediations that the subject has taken since the previous visit
Record an y serious adverse events and all adverse events occurring since the previous visit
If the Unscheduled visit is performed for the sole purpose of distribution of study  drug, the 
assessments noted above do not need to be performed.
6.4.6. Follow -Up Visit (±5 days)
Subjects will return for a Follow -Up visit, four weeks after the date of last dose of study  drug s.
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the Follow -up visit to ensure an 
approximate [ADDRESS_1008946] prior to the blood sample collection under fasti ng condition th e next 
morning.
The following will be performed and documented at this visit (±5days):
Symptom driven phy sical examination
Record vital signs, and body  weight
Obtain blood samples for:
Chemistry
Hematology
Coagulation Panel
Lipid Profile
GS-0976 
Protocol GS-US-426 -3989 
[COMPANY_009] Sciences, Inc. 
• Ur ine pregnancy test for female subjects of child bearing potential only Final 
Amendment 1 
• Reco rd all concomita nt medicat ions th at the su bject has taken since the previo us visit 
• Reco rd any serious adve rse events and a ll adverse occmT ing since the pr evious visit 
6.5. Assessment s for Premature Discontinuation from Study 
Subjects prem atmely discont inuing from the study (for example, as a result of an AE), shou ld 
have an Early Tennination ( ET) visit, if possib le, and a Follow-Up visit [ADDRESS_1008947] dose of study dmgs. The study assessme nts to be perfo1med at the ET visit are the same as 
those perfonned at the Week 12 visit (refe r to Sectio n 6.4.4 ). The study assessme nts to be 
perfo1med at the Follow -Up visit are listed in Sectio n 6.4.6. The subject will then be withdraw n 
from the study. 
If these visits are n ot possible or acceptable to the su bject or investigato r, the su bject may be 
withdraw n from the study. 
6.6. Criteria for Discontinuation of Study Treatment 
Study medicat ion may be discont inued in the following instances: 
• IntercmTe nt illness that would, in the judgme nt of the investigator , affect assessme nts of 
clinical status to a significa nt degree. Following resolution of intercunent illness, the su bject 
may resume study dosing at the discretion of the investigator. 
• Un acceptable toxic ity, or toxicity that, in the judgme nt of the investigato r, compromises the 
ability to continue study-specific proced mes or is considered to not be in the subject 's best 
interest 
• Su bject request to discontinue for any r eason 
• Su bject noncomplia nce 
• Pr egna ncy dming the study; refer to Appendix 3. 
• Sponsor discretion 
• Discont inuation of the study at the r equest of [COMPANY_009], a regulato1y agency or an institutional 
review board or independe nt ethics committee (IRB/IEC) 
6.7. 
CONFIDENTIAL Page48 [ADDRESS_1008948] is in a fasted state . Subjects will take their dose of study diugs after the study 
visit h as concl uded. 
Chemistiy: 
Alanine aininoti·a nsferase (ALT), aspartate aminotl'ansferase (AST) , albumin, alkaline 
phosp hatase (ALP), bicarbonate, blood urea niti·ogen (BUN) , calci um, c hloride, creatin ine, 
glucose, lactate dehydi·oge nase (LDH ), magnesi um, phosp horns, potassi um, sodium , total and 
direct bilirnbin, total prote in, uric acid, gamma -glutamyl ti· ansferase (GGT) . Also includes 
C-Peptide and Insulin for the Baseli ne/Day! , Week 4, and 12 visits . 
Creat inine cleara nce is calcu lated by [CONTACT_16424] -Gault equation {Cockcroft 1976 } using actual 
body weig ht (BW). The calculation will be perfonned by [CONTACT_738410] ·al laborato1y. 
Hemato logy: 
Hematoc rit (Hct), Hemog lobin (Hb ), Platelet count, Red blood cell count (RBC), White blood 
cell count (WBC) with diffe renti al (abso lute and percentage) including Lymphocytes, 
Monocytes , Neutl'ophils, Eosinophils, and Basoph ils and, Reticulocyte count and mean 
corpuscular volume (MCV) . 
Coag ulation Panel: 
INR, Prothrombin time (PT), paiiia l thromboplastin time (PTT) 
Pregna ncy Tests: 
Sernm P-hCG or urine P-hCG (if positive, requires immediate confomatio n with Sernm P-hCG) 
Additio nal Tests: 
Lipid Profi le, Hemog lobin Ale, HIV-I , H BV & HCV Serology (ifHCV A~ 
s),sern1 ~ 
and genomic samp le 
CONFIDENTIAL Page49 15 December 2016 
GS-0976 
Protocol GS-US-426 -3989 
[COMPANY_009] Sciences , Inc. 
Biomarkers: Final 
Amendment 1 
fucluding but not limited to: CK18 (M30 and M65), FGF 19, C4, Apolipoprotein B (Apo B), 
metabolite profi le, bile acids , stool microbiome, blood miRNA , NMR lipopro file, free fatty 
acids, ELF™ Test , and FibroSURE/FibroTest®. 
Phaimacok inetic (PK) Assessme nts: 
Sing le PK Sampling 
Sing le PK samples will be collected and ai·chived for PK analysis of GS-0976 and other 
metabolites as applicable 
6.8.2. Physical Examination 
A complete physical exam ination sh ould include source documentation of general appearance, 
and the following body systems: h ead, neck, and thyroid ; eyes, eai·s, nose, throat, mout h, and 
tongue; ch est ( excluding breasts); respi[INVESTIGATOR_141876] 1y; cai·diovasc ulai·; lymp h nodes; abdomen; skin, hair, 
nails ; mu sculoskeleta l; neurological. 
The focus of a symptom drive n ph ysical examinatio n will be detennined by [CONTACT_20616] r 
based on subject complaint. For example, if a subject complains of a cough, a lung exam shou ld 
be perfonned. If consistent with pn eumonia (rales /crack les on exam) then an AE would be 
documented. 
Height, body weight, and hip circumfere nce will be collected at specified time points. 
6.8.3. Vital Signs 
Assessme nt of vital signs will include meas urement of resting blood pressure, pulse, respi[INVESTIGATOR_141876]1y 
rate and temperat ure. 
Blood pressure will be measured using the following standardized process: 
• Su bject shou ld sit for 5 minu tes with feet flat on the floor and meas urement aim suppo1 ied 
so that the midpo int of the manomete r cuff is at heaii level; 
• Use a mercmy sphygmo manomete r or au tomat ic blood press ure device with an ap propriately 
sized cuff with the bl adder centered over the brachia! a1ie1y; 
Measure and r ecord the bl ood pressure to the n earest [ADDRESS_1008949] whole num ber on an au tomat ic device. 
CONFIDENTIAL Page 50 15 December 2016 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 51 15 December [ZIP_CODE].8.4. Medical History
Medical histor y, including details regarding illnesses and allergies, date(s) of onset, and whether 
condition(s) is current ly ongoing, and medication history will be co llected on all subjects during 
Screening. If available, historical liver biopsy  information will also be 
collected.
6.8.5. Pharmacogenomic Testing
From subjects who agree to participate and provide consent, one blood sample will be obtained. 
This sample should be collected at the Day  1 visit, but may  be collected at any  time during the 
study  or at a separate poststu dy visit, if necessary . 
6.8.6. Health Related Quality of Life (HRQoL)
It is recommended that these questionnaires be completed prior to the clinical and laboratory  
assessments. The subject should read the questionnaires b y himself/herself and record the 
answers by [CONTACT_199616]/herself.
[IP_ADDRESS]. SF-[ADDRESS_1008950]’s point of view and consists of eight health domains (phy sical functioning, role -physical, 
bodily  pain, general h ealth, vitality , social functioning, role -emotional, and mental health). These 
health domain scales contribute to the phy sical health and mental health summary  measures.
[IP_ADDRESS]. CLDQ
The CL DQ asks 29 questions related to liver disease to measure health related qu ality of life in 
subjects with chronic liver disease.
[IP_ADDRESS]. WPAI
The Work Productivity  and Activity  Impairment (WPAI ) questionnaire asks [ADDRESS_1008951] of NASH on a person’s ability  to work and perform regular activities. 
6.8.7. Electrocardiogram
Standard 12-lead electrocardiogram (ECG) assessments will be performed. The Investigator will 
review the ECGs for an y clinically  significant abnormalities to ensure subject safety . Abnormal 
ECG findings that are considered clinicall y significant b y the Invest igator and meet the 
definition of an AE should be reported and recorded in the AE eCRF page.
6.8.8. FibroS can®
The sites will perform liver stiffness assessments by  [CONTACT_738411]®.It is required t hat each subject 
have the FibroS can®assessments done with the same type of probe at Baseline Day  1 and 
Week 12 visits (if available) .
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 52 15 December [ZIP_CODE].8.9. MRE and MRI -PDFF
Liver stiffness will be assessed b y MRE (shear wave 60 Hz) and the degree of steatosis will be 
measured b y Magnetic Resonance Imaging -Proton Density  Fat Fraction (MRI -PDFF ). These 
assessments can occur sequentially .
The MRE and MRI -PDFF images will be analy zed by  a central reader. 
Please refer to the Stud y Reference Binder for MRE and MRI -PDFF imaging guidelines. 
6.9. End of Study Definition
Subjects are considered to have completed t he study  after the completion of the Week [ADDRESS_1008952] a ca usal relationship with the treatment. An AE can 
therefore be an y unfavorable and/or unintended sign, s ymptom, or disease temporally  associated 
with the use of a medicinal product, whether or not considered re lated to the medicinal product. 
AEs may  also inc lude pre -or posttreatment complications that occur as a result of protocol 
specified procedures, overdose ,drug abuse/misuse reports , or occupational exposure . Preexisting 
events that increase in severity  or change in nature during or as a consequence of participation in 
the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, and transfusion. 
The condition that ledto the procedure may  be an AE and must be reported.
Preexisting diseases, conditions, or laboratory  abnormalities present or detected before the 
Screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (eg ,hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.6.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol- associated procedure is not an 
AE. I t is considered to be preexisting and should be documented on the medical history  
eCRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following :
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospi[INVESTIGATOR_1081]
Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 54 15 December 2016A medicall y important event or reaction: such events may  not be i mmediately  life-threatening or 
result in death or hospi[INVESTIGATOR_738392]. Medical and scientific judgment must be 
exercised to determine whether such an event is a reportable under expedited reporting rules. 
Examples of m edically  important e vents include intensive treatment in an emergency  room or at 
home for allergic bronchospasm; blood dy
scrasias or convulsions that do not result in 
hospi[INVESTIGATOR_059]; anddevelopment of drug dependency  or drug abuse. For the avoidance of doubt, 
infections resulting from contaminated medicinal product will be considered a medicall y 
important event and subject to expedited reporting requirements.
7.1.3. Clinical Laboratory Abnor malities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study  drug interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorde d as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.[ADDRESS_1008953] the syndrome or diagnosis (eg, an emia), not 
the laboratory  result (ie, decreased hemoglobin).
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to study  
drugs using clinical judgment and the following considerations:
No: Evide nce exists that the AE has an etiology  other than the study  drugs. For SAEs, an 
alternative causality  must be provided (eg, preexisting condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by [CONTACT_738412].
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of AE reporting. 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 55 15 December 2016The relationship to study  procedures (eg, invasive procedure s such as ven ipuncture ) should be 
assessed using the following considerations:
No: Evidence exists that the AE has an etiology  other than the study  procedure.
Yes: The AEoccurred as a result of protocol procedures, (eg,venipun cture)
7.2.2. Assessment of Severity
The severi ty grading of AEs will be assessed as Grade 1, 2, 3, 4 , or 5 according to the 
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, which can be found 
at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_8.5x11.pdf
(see Appendix 4).
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory  abnormality .
The distinction between the seriousness and the severity  of an adverse event should be noted. 
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For 
example, a headache may be severe in intensity , but would no t be classified as serious unless it 
met one of the criteria for serious events listed above.
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009]
After informed consent, but prior to initiation of st udy medication, the following t ypes of events 
should be report ed on the case report form (eCRF): all SAEs and AE related to 
protocol -mandated procedures.
[IP_ADDRESS]. Adverse Events
Following initiation of study  medication until [ADDRESS_1008954] that certain AEs be followe d bey ond the protocol defined 
follow -up period.
[IP_ADDRESS]. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the study (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol - required post treatment follow -up peri od, must be reported to the 
eCRF database and [COMPANY_009] Drug Safet y and Public Health ( DSPH )as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures perfo rmed after ICF is signed.
GS-0976 
Protoco l GS-US-426 -3989 
[COMPANY_009] Sciences , Inc. Final 
Amendment 1 
Any SAEs and deaths th at occur after the posttr·eatment follow-up visit but within [ADDRESS_1008955] dose of study diugs, regardless of causality, sho uld also be repo1 ied. 
Investigators are not o bligated to actively seek SAEs after the protoco l defined follow-up period, 
howeve r, if the investigator learns of any SAEs that occur after study parti cipation h as concluded 
and the event is deemed relevant to th e use of study di11gs, he/she sho uld promptly document and 
repo1 i the event to [COMPANY_009] DSPH. 
• A ll AEs and SAEs w ill be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline. 
[IP_ADDRESS]. Elech'onic Serious Ad verse E vent ( eSAE) Repo1 iing Process 
• Site personnel record all SAE data in the eCRF database and from there tr·ansmit the SAE 
infonnation to [COMPANY_009] DSPH within 24 ho urs of the investigator 's knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines. 
• If for any rea son it is not possible to record the SAE infonnation elech'onically, i.e., the 
eCRF database is not functioning, record the SAE on the paper serious ad verse event 
repo1 i ing fo1m and s ubmi t wit hin 24 hours to: 
[COMPANY_009] DSPH Fax: IPI[INVESTIGATOR_738393]: IPI[CONTACT_4002] 
• As soon as it is possibl e to do so, any SAE repo rted via paper must be tr·anscribed into the 
eCRF Database acco rding to instructions in the eCRF completion g uidelines. 
• If an SAE has been repo1ied via a paper fonn beca use the eCRF database has been locked, no 
fuither action is necess aiy. 
• For fatal or life-threatening events, copi[INVESTIGATOR_449680]1 is, autopsy repo1 is, and o ther 
documents are al so to be submitted by e-mail or fax when re quested and a pplicable. 
Tran smission of such documents sho uld occur witho ut perso nal s ubject identification, 
main taining the tr·acea bility of a document to the subject identifiers. 
• Addit ional infonnation m ay be requested to ensure the timely comple tion of accurate safety 
repo1 is. 
• Any medications necess aiy for tr·eatment of the SAE must be recorded onto the concomitant 
medica tion section of the su bject's eCRF and the event description section of the SAE fonn. 
7.4. [COMPANY_009] Reporting Requirement s 
Depe nding on rel evant local legislation or r egulations, includin g the a pplicable US FDA Code of 
Federal Regulations, the European Union (E U) Clinical Trials Directive (2001/20/EC) and 
relevant updates , and o ther country -spec ific legislation or r egulations, [COMPANY_009] may be required to 
CONFIDENTIAL Page 56 15 December 2016 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 57 15 December 2016expedite to worldwide regulatory  agencies reports of SAEs , serious adverse drug reactions 
(SADRs), or suspected u nexpected serious a dverse reactions (S[LOCATION_003]Rs). In accordance with the 
EU Clinical Trials Directive (2001/20/EC), [COMPANY_009] or a specified designee will notify  worldwide 
regulatory  agencies and the relevant IECin concerned Member States of applic able S[LOCATION_003]Rs as 
outlined in current regulations.
Assessment of e xpectedness forSAEs will be determined by  [CONTACT_122035] . 
All investigators will receive a safet y letter notify ing them of relevant S[LOCATION_003]R reports associated 
with any  study  drugs . The investigator should notify  the IRB or IEC 
of S[LOCATION_003]R reports as soon 
as is practical, where this is required b y local regulatory agencies, and in accordance with the 
local institut ional policy . 
7.5. Toxicity Management 
Observation for Drug Induced Liver Injury  (DILI):
Although subjects randomized in this study  will have baseline liver disease, their hepatic 
function should not be significantly  impaired. However, at baseline, some may  have liver 
biochemistry  levels above the upper limit of normal (ULN). 
For subjects with ALT and AST below ULN at study  start, close observation for DILI 
(asdescribed below) should be considered in subjects with an y of the following criteria (all labs 
confirmed b y repeat testing):
ALT or AST > [ADDRESS_1008956] at any  time
Total bilirubin > [ADDRESS_1008957]
ALP>[ADDRESS_1008958]
INR >1.5 x UL N (except for subjects on anticoagulant therapy )  
Clinical signs or symptoms that are, in the opi[INVESTIGATOR_871], consistent with 
hepatitis (such as right upper quadrant discomfort, fever, nausea, vomiting, jaundice, rash, or 
eosinophilia > 5%)
For subjects with ALT or AST between [ADDRESS_1008959] at study  start, close observation for DILI 
(as described below) should be considered in subje cts with an y of the following criteria (all labs 
confirmed b y repeat testing):
ALT or AST > 2 x baseline at an y time
Total bilirubin > [ADDRESS_1008960]  
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 58 15 December 2016ALP>[ADDRESS_1008961]
INR >1.5 x UL N (except for subjects on anticoagulant therapy )  
Clinical signs or symptoms that are, in the opi[INVESTIGATOR_871], consistent with 
hepatitis (such as right upper quadrant discomfort, fever, nausea, vomiting, jaundice, rash, or 
eosinophilia > 5%).  
Close observation includes:
Repeating liver bioch emistries (ALT, AST, ALP, total bilirubin, INR) within 48 hours
Obtaining a more detailed history  of symptoms and prior or concurrent disease
Obtaining a history  of concomitant drug use (including nonprescription medications and 
herbal and dietary  suppleme nt preparations), alcohol use, recreational drug use, and special 
diets
Obtaining a history  of exposure to environmental chemical agents
Ruling out other causes of liver disease as needed (obtain viral hepatitis panel, imaging for 
evaluation of biliary  tract disease, etc. if required in the opi[INVESTIGATOR_550232])
Continue to monitor liver biochemistries twice weekly. Frequency can decrease to once a 
week or less if abnormalities stabilize or study  drug s have been discontinued and subject is 
asymptomatic
During a period of close observation, study  drug s can be continued, if desired, at the discretion 
of the principal investigator . 
However, for all subjects, study  drug sshould be withheld if any  of the following criteria are met:
ALT or AST > [ADDRESS_1008962] AND either Total bilirubin > 2 x UL N or INR > 1.5 (in subjects not 
on anticoagulation)
ALT or AST > [ADDRESS_1008963] AND the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
ALT or AST > 
[ADDRESS_1008964] 
ALT or AST > [ADDRESS_1008965] for more than 2 weeks
AND
No other cause for the combination of laboratory  abnormalities is immediately  apparent 
(e.g. prolonged INR with warfarin use) important potential causes or contributors to 
abnormal AST/ALT or total bilirubin values include, but are not limited to:
Obstructive gall bladder or bile duct disease
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 59 15 December 2016Viral or alcoholic hepatitis (e.g. hepatitis A/B/C/D/E, Epstein -Barr virus, 
cytomegalovirus, herpes simplex virus, varicella)
Autoimmune hepatitis
Concomitant adm inistration of other hepatotoxins, including excessive doses of 
acetaminophen, drugs that inhibit bilirubin glucuronidation (e.g. indinavir, atazanavir, 
irinotecan), or herbal or dietary  supplements
Hypoxic or ischemic hepatopathy  or congestive hepatopathy in association with 
significant right -sided heart failure
Wilson disease
Progression of malignancy involving the liver (note that metastatic disease to the liver, by  
[CONTACT_5071], should not be used as an explanation for significant AST/ALT elevations)
If study drugs are withheld, they  may  be reintroduced with approval from the [COMPANY_009] Medical 
Monitor.
Treatment -emergent toxicities will be noted by  [CONTACT_550248]. Whether or not considered treatment -related, a ll subjects experiencing AEs 
must be monitored periodically  until sy mptoms subside, any  abnormal laboratory  values have 
resolved or returned to baseline levels or they  are considered irreversible, or until there is a 
satisfactory  explanation for the change s observed. Other than in the case of the liver enzy mes 
noted above, Grade [ADDRESS_1008966] results. For AEs associated with laboratory  abnormalities, the event should be 
graded on the basis of the clinical severity  in the context of the underly ing conditions; this may  
or may  not be in agreement with the grading of the laboratory  abnormality . Any questions 
regarding toxicity  management should be directed to the Medical Monitor.
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, reports 
of AEs associated with product complaints, occupational exposure with an AE, pregnancy  
reports regardless of an associated AE, and an AE in an infant following exposure from 
breastfeeding.  
Medication error is an y unintentional error in the prescribing, dispensing ,or administration of a 
medicinal product while in the control of the health care provider , subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
GS-[ADDRESS_1008967] labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose wi ll be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has t aken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
Occupational exposure is defined as exposure to a medicinal product as a result of one’s 
professional or non- professional occupation.
7.6.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study  drug follow - up 
period, to [COMPANY_009] DSPH by [CONTACT_738413] 24 hours of becoming aware of the pregnancy . 
Refe r to S ection 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premat ure termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in [ADDRESS_1008968] information is as follows: 
Email:  and Fax: 
[COMPANY_003]
[COMPANY_003]
GS-[ADDRESS_1008969] shou ld 
continue until the conclusion of the pr egnancy. If the end of the pregnancy occurs after the study 
has been comJ)lete d, the o utcome shou ld be reJ)orted directly to [COMPANY_009] DSPH, fax number 
IPI[INVESTIGATOR_738394] l IPD 
Refe r to Append ix 3 for Pregnancy Precautio ns, D efinition for Female of Childbea ring Potential, 
and Contraceptive Requirements. 
[IP_ADDRESS]. Repo1iing Othe r Special Situatio ns 
All special situatio ns repo1is (SSRs) will be recorded in the eCRF database within the time lines 
outlined in the eCRF completion gu ideline. 
Electro nic Special Situat ions Repo1 i ( eSSR) R epo1i ing Process 
• Site perso nnel record all SSR data in the eCRF database and from there trans mit the SSR 
infonnation to [COMPANY_009] DSPH within 24 hours of the investigato r 's knowledge of the event. 
Detai led instructio ns can be found in the eCRF completio n guidelines. 
• If for any reaso n it is not possible to record the SSR infonnation electr·o nically , i.e., the eCRF 
database is not functioning, record the SSR on the paper serious adve rse event repo1i ing fonn 
and subinit within 24 hours to: 
[COMPANY_009] DSPH: Emai l: IPI[INVESTIGATOR_738395]: IPD 
As soon as it is poss ible to do so, any SSR repo1ied via pape r mu st be tr· anscribed into the eCRF 
Database accord ing to instructio ns in the eCRF completion guidelines. 
If an SSR has bee n reported via a paper fo1 m beca use the eCRF database has bee n locked , no 
fuither action is necessaiy. 
These repo1is must consist of situatio ns th at involve study diugs and/o r [COMPANY_009] concomitant 
medicat ions, but do not apply to non-[COMPANY_009] concomitant medications. 
Specia l situ ations involving non -[COMPANY_009] concoinita nt medicat ions d oes not need to be repo1ied on 
the sp ecial situat ions repo1 i fonn; howeve r, for special situat ions th at result in AEs due to a 
non-[COMPANY_009] concomitant medicatio n, the AE shou ld be repo1ied on the AE fonn. 
Any inappropriate use of concoinita nt medicat ions prohibited by [CONTACT_648740]1ied as "Inis use," but may be more appropriately documented as a protoco l deviatio n. 
Refe r to Section 7.3 and the eCRF comp letion gu idelines for full instmctions on the mechanism 
of specia l situ ations repo1i ing. 
All clinical sequelae in relation to these special situation repo1is will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE repo1i fo1m. Details of the symptolilS and 
signs, clinical management , and ou tcome will be repo1ied, when available. 
CONFIDENTIAL Page 61 15 December 2016 
GS-0976 
Protocol GS-US-426 -3989 
[COMPANY_009] Sciences, Inc. 
8. STATISTICAL CONSIDERATIONS 
Detai ls will be prov ided in the statistical analys is plan (SAP). 
8.1. 
8.1.1. Anal ysis Objecti ves and Endpoint s 
Anal ysis Objecti ves 
The primary objective of this study is as follows : 
• To evaluate the safety and tolerability of GS-097 6 in subjects with NAS H. 
The explorato1y objectives of this study are as follows: 
8.1.2. Primar y Endpoint 
The prima1 y endpo int is the safety of GS-[ADDRESS_1008970] data will be listed as measured.  All statistical summ aries and analy ses will 
be performed using SAS®software (SAS Institute, Cary , North Carolina, [LOCATION_003]).
8.2.1. Analysis Sets
[IP_ADDRESS]. Efficacy
The primary  anal ysis set for efficacy  anal ysis is defined as the Full Anal ysis Set (FAS), which 
includes all subjects who were randomized into the study and received at least 1 dose of study  
drugs.
Subjects who receive study  drug sother than that to which they  were assigned for the entire 
duration of treatment, will be anal yzed according to the treatment group they  were randomized .
[IP_ADDRESS]. Safety
The primary  anal ysis set for safety anal yses is defined as all subjects who received at least 
onedose of stud y drug s. Subjects who receive study  drug sother than that to which they  were 
assigned for the entire duration of treatment, will be analyzed according to the study  drug s
received.
All data collected during treatment plus [ADDRESS_1008971] dose of stud y drug s will be included in 
the safet y summaries .
CCI
GS-0976 
Protocol GS-US-426 -3989 
[COMPANY_009] Sciences , Inc. 
[IP_ADDRESS]. Phaimacok inetics Final 
Amendment 1 
There are two phaimacok inetic analysis sets: 1) The PK an alysis set which inclu des 
concentrat ion data from the sin le sam les draw n at each visit 
The PK analysis set will include all random ized subjects who took at least one dose of study 
diugs and for wh om concentratio n data of analytes GS-0976 (an d its metabolites as applicable) 
are available. The PK an alysis set will be used for analyses of population P K. 
[IP_ADDRESS]. Biom ai·kers 
The Bioma rker Analysis Set will include data from subjects in the Safety Analysis Set who h ave 
th e necessaiy base line and on-study measureme nts to provide interpretab le results for the 
specific parameters of interest. 
8.3. Data Handling Conventions 
Miss ing data can have an im pact on the inte1 p retation of the tr ial data. In general, values for 
miss ing data will not be imputed. 
Whe re approp riate, safety data for subjects that did n ot complete the study will be included in 
summa ry statist ics. For example , if a subject received study medicat ion, the su bject will be 
included in a summaiy of adverse events acco rding to the treatme nt received; othe1wise, if the 
subject is not dosed then they will be excluded from the su mma 1y. If safety laborato [ADDRESS_1008972] ai·e miss ing for any reaso n at a time point , the subject will be excluded from the 
calculatio n of summaiy statistics for that time point. If the su bject is missing a pre- dose value, 
then the subject will be excluded from the calcu lation of summaiy statistics for the pr e-dose 
value and the chan ge from pre-dose values. 
Values for miss ing safety laborato 1 y data will not be imputed ; howeve r, a mi ssing baseline result 
will be replaced with a Scree ning result, if available. If no pr e-treatme nt laborato 1 y value is 
available, the baseline value will be assumed to be n01ma l (ie, no grade [Grade O]) for the 
summa ry of graded laborato 1 y abno1malities. 
Values for miss ing vital signs data will not be imputed ; howeve r, a mi ssing base line result will 
be replaced with a Scree ning result, if available. 
CONFIDENTIAL Page [ADDRESS_1008973] descriptive 
methods. 
Demographic summaries will include sex, race/ethnicity , and age.
Baseline data will include a summary  of bod y weight, height, bod y mass index , and 
randomization stratification group (presence or absence of diabetes), and other disease 
characteristic varia bles.
8.5. Efficacy Analysis
The biological activity  of GS-0976 will be evaluated using radiologic and biochemical endpoints 
andbiomarker variables. Because efficacy  endpoints will be evaluated for exploratory  purpose, 
formal statistical comparisons will not be made for these endpoints. Point estimates and 
ninety -five percent confidence intervals (95% CI) will be provided if applicable.
8.6. Safety Analysis
All safet y data collected on or after the date that GS-[ADDRESS_1008974]’s extent of exposure to GS - 0976 will be generated from the study  drug 
administration eCRF. Exposure data will be summarized by  [CONTACT_1570]. 
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). System Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database. Adverse event severity  will be graded using the CTCAE 
Version 4.03.
Events will be sum marized on the basis of the date of onset for the event. A treatment -emergent 
adverse event (TEAE) will be defined as 1 or both of the following:
Any AEs with an onset date on or after the start date of study  drugs and no later than 30 days 
after permanent discontinuation of study  drug.
Any AEs leading to premature discontinuation of study  drugs.
Summaries (number and percentage of subjects) of TEAEs by  [CONTACT_53844] . 
Treatment -emergent AEs will also be summarized by  [CONTACT_454190] . In 
addition, TEAEs leading to premature discontinuation of study  drug and study  will be 
summarized and listed.
GS-0976 
Protoco l GS-US-426 -3989 
[COMPANY_009] Sciences , Inc. Final 
Amendment 1 
All AEs collected during the course of the study will be prese nted in data listings with a field for 
treatment-emergent event (yes/no). 
8.6.3. Laborator y Evaluations 
Selected laborato1y data will be summ arized (n, m ean, SD, Median , Ql , Q3, minim um, and 
maximum ) by [CONTACT_738414]. 
Graded laborato 1 y abnonnalities will be defined using the grading scheme in the CTCAE 
Versio n 4.03 (refer to Appendix 4). Gradi ng oflaborato1y abnonnalities for analysis purp oses 
will be perfo nned by [CONTACT_738415] 1y. 
fucidence of treatme nt-emer gent laborato1y abnonnalities, defined as values that increase at least 
[ADDRESS_1008975] dose 
of study diugs plus 30 days will be summ arized by [CONTACT_34689]. If basel ine data are missing, 
then any graded abnonnality (ie, at least a Grade 1) will be considered treatme nt emer gent. 
8.6.4. Other Safety Evaluation s 
The number and perce ntage of subjects deve lopi[INVESTIGATOR_738396]-[ADDRESS_1008976] atistics for the 12-lead ECGs perfo1med at Baseline and Week 12 
will be generate d. 
8.7. Pharmacokinetic Anal ysis 
Plasma conce ntratio ns and phannacokinetic paraineters (eg, AUCtau , Cmax and Ctau) will be listed 
and summai· ized as appropriate for GS-0976 (and its metabolites as applicable) using descr iptive 
statistics. 
Detai ls of the analysis plan will be provide d in the ph aimacokinetic repo1 iing and anal ysis plan . 
8.8. Biomarker Anal ysis 
Descr iptive statistics of bioma rker expression and change from baseline will be provided at each 
sainpling time by [CONTACT_221062]. Point estimates and 95% confidence intervals may be calculated. 
8.9. Sample Size 
Due to the explorato1y nature of this study, no fo1mal power calculations were used to dete1min e 
sainple size. The number of subjects was chosen based on clinical exper ience with other similar 
CONFIDENTIAL Page 66 15 December 2016 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 67 15 December 2016proof of concept studies . However, assuming that 4% of subjects in the placebo arm (N=25) and 
32% in the GS -0976 20 mg arm (N=50 ) have a ≥ 30% reduction in MRI -PDFF at Week 12, this 
sample size will provide 80% power to detect the difference based on a two- sided Fisher’s exact 
test at a significance level of 0.05.
8.10.
Data Monitoring Committee
An independent, external data monitoring committee (DMC) that consists of two hepatologists 
and a PhD statistician will review the progress of the study  and perform reviews of safety  data. 
The DMC will convene onc e [ADDRESS_1008977] 3 similar Grade ≥ 3 serious, treatment related Common Terminology  
Criteria for Adverse Events (CTCAE) observed in the trial. In the event of two similar Grade 
4-CTCAE treatment related events or one Grade [ADDRESS_1008978] 
interests of the participants, whether the stud y should continue as planned, or the study should 
continue with modifications. The DMC may  also provide recommendations as needed regarding 
study  design.
The DMC’s specific activities will be defined b y a mutually  agreed charter, which will define the 
DMC’s membership, conduct and meeting schedule.
While the DMC will be asked to advise [COMPANY_009] regard ing future conduct of the study , including 
possible earl y study termination, [COMPANY_009] retains final decision -making authority  on all aspects of 
the study .
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 68 15 December [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country  in which the research is conducted, whichever affords the greater 
protection to the study  subject. The investigator will ensure adherence to the basic principles of 
Good Clinical Practice, as outlined in 21 CFR 312, subpart D, “Responsibilitie s of Sponsors and 
Investigators,” 21 CFR, part 50, "Protection of Human Subjects" , and 21 CFR, part 56, 
"Institutional Review Boards" .
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, 
"Financial Disclosure b y Clinical Investigators", providing documentation of their financial 
interest or arrangements with [COMPANY_009], or proprietary interests in the study  drugs under study . This 
documentation must be provided prior to the investigator’s (and an y subinvestigator’s) 
participat ion in the study . The investigator and subinvestigator agree to notify  [COMPANY_009] of any  
change in reportable interests during the study  and for [ADDRESS_1008979] (IRB)/Independent Ethics Committee (EC) 
Review and Approval
The investigator (or Sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y acc
ompany ing material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB. The investigator will not begin an y stud y subject activities until 
approval from the IRB has been documented and provided as a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRBany modifications made to the protocol or any accompan ying material to be provided to 
the subject after initial IRB approval, with the exception of those necessary to reduce immediate 
risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. The 
investigator must use the most current IRB-approved consent form for documenting written 
informe d consent. Each informed consent (or assent as applicable) will be appropriatel y signed 
GS-[ADDRESS_1008980]’s legally authorized representative and the person 
conducting the consent discussion, and also by  [CONTACT_738416]. The consent form will inform subjects about sample retention.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed by [CONTACT_1769]) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB, or laboratory . Laboratory  specimens 
must be labeled in su ch a way  as to protect subject identity  while allowing the results to be 
recorded to the proper subject. Refer to specific laboratory instructions . NOTE: The investigator 
must keep a S creening log showing codes, names, and addresses for all subjects screen ed and for 
all subjects randomized in the trial. Subject data will be processed in accordance with all 
applicable regulations. 
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator brochure, this protocol, eCRF, the study  drugs, and any  other study  information, 
remain the sole and exclusive propert y of [COMPANY_009] during the conduct of the study and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents direct ly 
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These docu ments should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, eCRF and query  forms, IRB
and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Document ation of the reason(s) a c onsented subject is not randomized
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 70 15 December 2016Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of study  drugs, including dates of dispensing and 
return;
Record of all AEs and other safety parameters (start and end date, and including causality 
and severit y);
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of stud y completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_1008981] approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no applicati on is filed or if the application is not 
approved for such indication, until [ADDRESS_1008982] has been randomized . Subsequent to data entry , a 
study  monitor will perform source dat a verification within the EDC sy stem. Original entries as 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 71 15 December 2016well as an y changes to data fields will be stored in the audit trail of the s ystem. Prior to database 
lock (or an y interim time points as described in the clinical data management plan), the 
investi gator will use his/her log in credentials to confirm that the forms have been reviewed, and 
that the entries accurately  reflect the information in the source documents. The eCRF capture the 
data required per the protocol schedule of events and procedures. System -generated or manual 
queries will be issued to the investigative site staff as data discrepancies are identified by  [CONTACT_550253], who routinel y review the data for completeness, correctness, and 
consistency . The site coordinat or is responsible for responding to the queries in a timely manner, 
within the sy stem, either by  [CONTACT_204983] , and 
providing the reason for the update (e .g.,data entry  error). At the conclusion of the trial , [COMPANY_009] 
will provide the site with a read -
only archive cop y of the data entered b y that site. This archive 
must be stored in accordance with the records retention requirements outlined in Section 9.1.5.
9.1.7. Study Drug Accountability and Return
[COMPANY_009] recommen ds that used and unused study  drug supplies be returned to the shippi[INVESTIGATOR_409746]. The study  monitor will provide instructions for 
return. If return is not possible, the study  monitor will evaluate each stud y center’s 
study  drug
disposal procedures and provide appropriate instruction for destruction of unused study  drug
supplies. I f the site has an appropriate standard operating procedure (SOP) for drug destruction
as determined b
y [COMPANY_009] QA , the site may  destro y used (empt yor partially  empty ) and unused 
study  drug supplies in accordance with th atsite’s approved SOP. A cop y of the site’s 
approved 
SOP will be obtained for central files. 
Ifstudy  drugs are destro yed on site, the investigator must maintain accurate records for all study  
drugs destroy ed. Records must show the identification and quantity  of each unit destroy ed, the 
method of destruction, and the person who disposed of the study  drugs. Upon study  completion, 
copi[INVESTIGATOR_738397]. Another copy  will be 
returned to [COMPANY_009] .
The study  monitor will review study  drug supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]’s appointed stud y monitors, to I RB,or to regulatory  authorit y or health authority  
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluation s described in this protocol.
GS-[ADDRESS_1008983] submit all protocol modifications to t heIRBin 
accordance with local requirements and receive documented IRB approval before modifications 
can be implemented.
9.2.2. Study Report 
A clinical study  report (CSR) will be prepared and provided to the regulatory  agency (ies). [COMPANY_009] 
will ensure that the r eport meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases. 
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, eg ,attendance at I nvestigator's Meetings. If required under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to Feder al and State agencies an y 
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance wi th regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular inter vals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the eCRF. The investigato r agrees to cooperate with the monitor to ensure 
that any  problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Monitoring and Oversight of Biomarker Specimens
Biomarker research specimens will be tracked in a manner consistent with Good Clinical 
Practice b y a quality -controlled, auditable, and appropriatel y validated laboratory information 
management s ystem, to ensure compliance with data confidentialit y as well as adherence to 
authorized use of specimens as specified in this pr otocol and in the Informed Consent Form.  
GS-[ADDRESS_1008984] of any  inspection or audit.
9.3.5. Study Discontinuation
Both the Sponsor and the investigator reserve the right to terminate the study at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and ECs. In terminating the study , [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-[ADDRESS_1008985] 2012;18 (1):29 -37.
Bannas P, Kramer H, Hernando D, Agni R, Cunningham AM, Mandal R, et al. Quantitative 
magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human 
livers. Hepatology  2015;62 (5):1444-55.
Bianchi A, Evans J L, Iverson AJ, Nordlund AC, Watts TD, Witters L A. Identification of an 
isozy mic form of acet yl-CoA carbox ylase. J Biol Chem 1990;265 (3):1502 -9.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Dietrich P, Hellerbrand C. Non -alcoholic fatt y liver disease, obesity and the metabolic s yndrome. 
Best practice & research 2014;28 (4):637-53.
Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non -alcoholic fatty  liver disease. 
QJM 2010;103 (2):71-83.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the 
strongest predictor for disease -specific mortality  in NAFLD after up to 33 y ears 
of follow -up. Hepatology 2015;61 (5):1547 -54.
Faramawi MF, Wildman RP, Gustat J, Rice J, Abdul Kareem MY. The association of the 
metabolic sy ndrome with QTc interval in NHANES III. Eur J Epi[INVESTIGATOR_5541] 2008;23 
(7):459-65.
Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, et al. Acet yl-CoA carbox ylase 
inhibition by  [INVESTIGATOR_47967]-630 reduces hepatic steatosis, improves insulin sensitivity , and 
modulates dy slipi[INVESTIGATOR_738398]. Proc Natl Acad Sci U S A 2016;113 (13):E1796-
805.
Harwood HJ, Jr. Treating the metabolic sy ndrome: acet yl-CoA carboxy lase inhibition. Expert 
opi[INVESTIGATOR_441219] 2005;9 (2):[ADDRESS_1008986], Savage DD, McNamara PM. Epi[INVESTIGATOR_122014]: the Framingham study . N Engl J Med 1982;306 (17):1018 -22.
Kim KH. Regulation of mammalian acet yl-coenzyme A carbox ylase. Annu Rev Nutr 
1997;17:77-99.
Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non -alcoholic steatohepatitis. Clin 
Chim Acta 2011;412 (15- 16):1297-305.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 75 15 December 2016Lambert D, Rouger C, Diebold MD, Ramaholimihaso F, Boulagnon C, Nguy en Y, et al. 
[Gastritis due to Helicobacter p ylori, an unusual cause of chronic diarrhoea in 
HIV infected patients] [French]. Medecine et maladies infectieuses 2014;44 
(2014):334-8.
Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance 
elastograph y predicts advanced fibrosis in patients with nonalcoholic fatt y liver 
disease: a prospective study . Hepatology  2014;60 (6):1920 -8.
Neuschwander -Tetri BA. Hepatic lipotoxicity  and the pathogene sis of nonalcoholic 
steatohepatitis: the central role of nontrigl yceride fatty  acid metabolites. 
Hepatology  2010;52 (2):774-88.
Ong JP, Younossi ZM. Epi[INVESTIGATOR_122015]. Clin L iver Dis 
2007;11 (1):[ADDRESS_1008987] R, Ramirez K, Fortney  L, et al. Magnetic 
Resonance Elastograph y vs Transient Elastography in Detection of Fibrosis and 
Noninvasive Measurement of Steatosis in Patients with Biopsy -proven 
Nonalcoholic Fatty  Liver Disease [Accepte d Manuscript]. Gastroenterology  2016.
Patel JR, Bettencourt R, Cui JY, Salotti J, Hooker J, Bhatt A, et al. Non -invasive quantitative 
decline in liver fat content on MRI  and histologic response in nonalcoholic 
steatohepatitis: A secondary  anal ysis of MOZAR T trial [Abstract 913]. American 
Assoication for the Study of L iver Diseases (AASLD); 2015 13 -17 November; 
San Francisco, CA. pp. 659A -60A.
Ratziu V, Massard J, Charlotte F, Messous D, Imbert -Bismut F, Bon yhay L, et al. Diagnostic 
value of biochemical mark ers (FibroTest -FibroSURE) for the prediction of liver 
fibrosis in patients with non -alcoholic fatty  liver disease. BMC gastroenterology  
2006;6:6.
Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in 
NAFLD/NASH. Free radical research 2013;47 (11):869-80.
Tong L, Harwood HJ, Jr. Acet yl-coenzy me A carboxy lases: versatile targets for drug discovery . 
J Cell Biochem 2006;99 (6).
Vernon G, Baranova A, Younossi ZM. S ystematic review: the epi[INVESTIGATOR_122016]-alcoholic fatty  liver disease and non -alcoholic steatohepatitis in adults. 
Aliment Pharmacol Ther 2011;34 (3):274 -
85.
Voulgari C, Tentolouris N, Papadogiannis D, Moyssakis I, Perrea D, Ky riaki D, et al. Increased 
left ventricular arrh ythmogenicity  in m etabolic s yndrome and relationship with 
myocardial performance, risk factors for atherosclerosis, and low -grade 
inflammation. Metabolism: clinical and experimental 2010;59 (2):159 -65.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 76 15 December 2016Wanless I R, Lentz JS. Fatty  liver hepatitis (steatohepatitis) and obesit y: an autopsy  study  with 
analysis of risk factors. Hepatology  1990;12 (5):1106-10.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of 
nonalcoholic fatt y liver disease and nonalcoholic steatohepatitis among a largely 
midd le-aged population utilizing ultrasound and liver biopsy : a prospective study . 
Gastroenterology  2011;140 (1):124-31.
Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapi[INVESTIGATOR_122017] 
U.S. Hepatology  2014;59 (6):2188
-95.
Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology  2014;147 
(4):754-64.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 77 15 December 201611. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Study Procedures Table for GS -US-426-3989
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Po
tential, and 
Contraceptive Re quirements
Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.[ADDRESS_1008988] this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copi[INVESTIGATOR_10805], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator N axne (Printed) Signature 
[CONTACT_738417]'ITAL Page 78 15 December 2016 
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 79 15 December 2016Appendix 2. Study Procedures Table for GS -US- 426-3989
Assessments ScreeningaBaseline / 
Day 1On-treatm ent VisitsFollow Up 
Visitb
(± 5 Days)Week 1
± 3 daysWeek 4
± 3 daysWeek 8
± 3 daysWeek 12 /ETb
± 7 days
Clinical Assessments
Written Informed ConsentcX
Determine Eligibility X X
Medical History X
Historical Liver Biopsy (If 
Available)X
Physical Examination X XdXdXdXdXdXd
Vital Signseincluding Weight X X X X X X X
Height X
Waist Circumference X X
12-lead ECG X X X
UltrasoundfX
MRE, MRI -PDFF X X
FibroS can®gX X
SF-36, WPAI, and CLDQ
QuestionnaireshX X
Adverse Events X X X X X X X
Concomitant Medications X X X X X X X
Dispense Study Drug s X X X
Revie w of Study Drug Dosing 
Com pliance (Pi[INVESTIGATOR_38950])X X X X
Laboratory Assessments
Subject FastingiX X X X X X X
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 80 15 December 2016Assessments ScreeningaBaseline / 
Day 1On-treatm ent VisitsFollow Up 
Visitb
(± 5 Days)Week 1
± 3 daysWeek 4
± 3 daysWeek 8
± 3 daysWeek 12 /ETb
± 7 days
Chemistry, Hematology , 
Coagulation PanelX X X X X X X
Lipid Profile X X X X X X
Pregnancy TestjX X X X X X
Serum FSHkX
Single PK Sampling X X X X
Hem oglobin A1c X X X
Blood and Urine Collection 
(Biomarker)X X X X
Stool Collection (Biomarker) X X
Urine Drug ScreeninglX
HIV-1, HBV & HCVmSerology X
Genomic SamplenX
a. Screening asse ssments to be completed within 6weeks prior to Day 1.  The Screening period also may be extended longer under special circumstances with the explicit 
approval of the [COMPANY_009] Medical Monitor.
b. Subjects discontinuing treatment at any time for any reason (Early Termination – ET) should complete the procedures listed for the Week 12/ET visit AND the Follow -Up 
visit.
c. Obtain written informed consent before initiation of any screening procedure.
d. Sympt om-driven physical examination
e. Vital signs include blood pressure, heart rate, respi[INVESTIGATOR_1487], and body temperature.
f. Ultrasound may be performed if necessary to confirm NAFLD.
g. Perform FibroS can®if available.
h. It is recommended that QoL questionnaires be completed prior to any study procedures being performed and prior to the subject seeing a health care provider. Refer to the 
Study Reference Binder for guidance on Q oL questionnaire administration for subjects with QoL questionnaires available at Baseline/Day 1.
i. Subjects must be in a fasted state at least 8 hours prior to blood coll ection.
j. Females of childbearing potential only (See Appendix 3). Serum p regnancy test at Screening and u rine pregnancy test at all other visits, except Week 1.
k.
l
.Drug screen for am phetamines, cocaine, and opi[INVESTIGATOR_858] (i .e., heroin, morphine).
m. HCV Ab positive, reflex to HCV RNA. 
n.
CCI
CCI
CCI
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 81 15 December 2016Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definitions of Childbearing Potential
For the purposes of this study , a female born subject is considere d of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically  documented ovarian failure.
Women are considered to be in a postmenopausal state when they  are > 54years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age with amenorrhea of > 12 months may also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpi[INVESTIGATOR_10822] a female subject of an y age.
b.Definitions of M ale Fertility
For the purposes of this study , a male born subject is considered fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchiectomy or medical documentation.
2)
Contraceptive Requirements for Female Subjects
a.Study Drug Effects on Pregnancy and Hormonal Contraception
The data of GS -[ADDRESS_1008989] version of the investigator’s brochure for 
GS-[ADDRESS_1008990] 
will be performed at the end of relevant s ystem exposure. In the event of a delay ed menstrual 
period (over one month between menstruations), a pregnancy test must be performed to rule ou t 
pregnancy .  This is even true for women of childbearing potential with infrequent or irregular 
GS-[ADDRESS_1008991] agree to one of the following from Screening until 30 day s 
following the las t dose of the study  drugs .
Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le. 
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Tubal sterilization
Essure micro- insert sy stem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least [ADDRESS_1008992] dose of the study  drugs .
3) C ontraceptive Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbe aring potential must use condoms 
during treatment until [ADDRESS_1008993] 90 days following the las t dose of study  drug s.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicide onl y, and 
lactat ional amenorrhea method (LAM). Female condom and male condom should not be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they become pregnant within 30 day s([ADDRESS_1008994]) of last 
study  drug dose. Subjects who become pregnant or who suspect that they  are pregnant during the 
study  must report the information to the investigator and discontinue study dru gsimmediatel y. 
Subjects whose partner has become pregnant or suspects she is pregnant during the stud y must 
report the information to the investigator. Instructions for reporting pregnancy , partner 
pregnancy , and pregnancy  outcome are outlined in Section 7.6.2.
GS-0976
Protocol GS -US-426-3989 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 83 15 December 2016Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) Version 
4.0 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010
-06-14_QuickReference_8.5x11.pdf